| scholarly article | Q13442814 |
| P50 | author | Valentín Fuster Carulla | Q977751 |
| Jonathan L. Halperin | Q6273626 | ||
| Alice K. Jacobs | Q21401828 | ||
| Cynthia R Adams | Q42260493 | ||
| Silvia Priori | Q42867536 | ||
| Juan Tamargo | Q43018353 | ||
| Kenneth Dickstein | Q43248428 | ||
| Keith McGregor | Q57004725 | ||
| Sidney C Smith | Q82174061 | ||
| Kenneth A. Ellenbogen | Q87446231 | ||
| Jeffery B Anderson | Q87687177 | ||
| Barbara Riegel | Q88041698 | ||
| David S Cannom | Q90625360 | ||
| Eric N Prystowsky | Q90690711 | ||
| Harry J. G. M. Crijns | Q110902217 | ||
| Jean-Yves Le Heuzey | Q110902712 | ||
| A. John Camm | Q110902795 | ||
| José Luis Zamorano | Q114244147 | ||
| John Lekakis | Q114244236 | ||
| Jaap W Deckers | Q114292239 | ||
| Rick Nishimura | Q114292248 | ||
| Joseph P. Ornato | Q114292250 | ||
| L Samuel Wann | Q114335902 | ||
| Catherine Despres | Q114561276 | ||
| Ady Osterspey | Q114561277 | ||
| Andrzej Budaj | Q60835867 | ||
| Elliott M Antman | Q64496972 | ||
| Marco Metra | Q39274051 | ||
| P2093 | author name string | Richard L Page | |
| Jonathan L Halperin | |||
| Jean-Jacques Blanc | |||
| Juan Luis Tamargo | |||
| Veronica Dean | |||
| Joao Morais | |||
| Sharon Ann Hunt | |||
| Anne B Curtis | |||
| G Neal Kay | |||
| S Bertil Olsson | |||
| James E Lowe | |||
| Lars E Rydén | |||
| P2860 | cites work | Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators | Q34506737 |
| Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. | Q34509672 | ||
| Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial | Q34512370 | ||
| Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol | Q34522261 | ||
| Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study | Q34533998 | ||
| ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardi | Q34542591 | ||
| Inflammation as a risk factor for atrial fibrillation | Q34543274 | ||
| Atrial fibrillation: strategies to control, combat, and cure | Q34544936 | ||
| A multicenter risk index for atrial fibrillation after cardiac surgery | Q34547092 | ||
| Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia | Q34548944 | ||
| Lifetime risk for development of atrial fibrillation: the Framingham Heart Study | Q34550202 | ||
| Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study | Q34557255 | ||
| Amiodarone versus sotalol for atrial fibrillation | Q34557369 | ||
| Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis | Q34558240 | ||
| Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation | Q34561536 | ||
| New antiarrhythmic drugs for the treatment of atrial fibrillation | Q34578147 | ||
| Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure | Q34620874 | ||
| Atrial fibrillation and congestive heart failure: specific considerations at the intersection of two common and important cardiac disease sets | Q34658801 | ||
| Electrical, contractile and structural remodeling during atrial fibrillation | Q34682882 | ||
| Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). | Q34682919 | ||
| Molecular mechanisms of remodeling in human atrial fibrillation. | Q34682996 | ||
| Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study | Q34727157 | ||
| Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study | Q34734292 | ||
| Stroke risk in an elderly population with atrial fibrillation | Q34749458 | ||
| New approaches to atrial fibrillation management: a critical review of a rapidly evolving field. | Q34978723 | ||
| Transient proarrhythmic state following atrioventricular junction radiofrequency ablation: pathophysiologic mechanisms and recommendations for management | Q35012980 | ||
| Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation | Q35057258 | ||
| Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy | Q35096835 | ||
| Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials | Q35096843 | ||
| Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis | Q35107044 | ||
| Pharmacological prevention of atrial tachycardia induced atrial remodeling as a potential therapeutic strategy. | Q35108457 | ||
| Atrial stunning: determinants and cellular mechanisms | Q35135992 | ||
| Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation | Q35136228 | ||
| Familial atrial fibrillation is a genetically heterogeneous disorder. | Q35160348 | ||
| Pharmacological Approaches in the Treatment of Atrial Fibrillation | Q22336981 | ||
| KCNQ1 gain-of-function mutation in familial atrial fibrillation | Q24338486 | ||
| The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results | Q24514937 | ||
| Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation | Q24534117 | ||
| An 8 1/2-year clinical experience with surgery for atrial fibrillation | Q24535788 | ||
| Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation | Q28162596 | ||
| Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: A meta-analysis and hypothesis | Q28162597 | ||
| Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation | Q28165271 | ||
| Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? | Q28166299 | ||
| Transient ischemic attacks in patients with atrial fibrillation: implications for secondary prevention: the European Atrial Fibrillation Trial and Stroke Prevention in Atrial Fibrillation III trial | Q28167478 | ||
| Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin | Q28171104 | ||
| Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study | Q28171184 | ||
| Use of antithrombotic agents during pregnancy | Q28175161 | ||
| Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves | Q28175186 | ||
| Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas | Q28176992 | ||
| Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications | Q28190230 | ||
| Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané; FFAACS) | Q28190393 | ||
| Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring | Q34327141 | ||
| A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement | Q34351655 | ||
| Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation | Q34396457 | ||
| Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators | Q34420012 | ||
| Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. | Q34430496 | ||
| Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke | Q34441229 | ||
| Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials | Q34496116 | ||
| Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial | Q34502430 | ||
| New ideas about atrial fibrillation 50 years on. | Q34503407 | ||
| Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies | Q40982204 | ||
| Paroxysmal atrial fibrillation: a need for classification | Q41004931 | ||
| Clinical implications of left atrial appendage flow patterns in nonrheumatic atrial fibrillation | Q41040819 | ||
| The cardiac muscle in the pulmonary vein of the rat: A morphological and electrophysiological study | Q41068677 | ||
| Disturbed secretion of atrial natriuretic peptide in patients with persistent atrial standstill: Endocrinologic silence | Q41129995 | ||
| Role of concealed and supernormal conductions during atrial fibrillation in the preexcitation syndrome | Q41171659 | ||
| Hypercoagulability and haemodynamic abnormalities in atrial fibrillation | Q41343151 | ||
| Long-term follow-up of direct current cardioversion after cardiac surgery with special reference to quinidine | Q41362581 | ||
| Atrioventricular node reentry: physiology and radiofrequency ablation | Q41372361 | ||
| Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies | Q41416463 | ||
| Factors predisposing to the development of atrial fibrillation | Q41633728 | ||
| Electrocardiographic and serum enzymic alterations associated with cardiac alterations induced in dogs by single transthoracic damped sinusoidal defibrillator shocks of various strengths | Q41660096 | ||
| Epidemiologic features of asymptomatic cerebral infarction in patients with nonvalvular atrial fibrillation | Q41775425 | ||
| Superiority of transesophageal echocardiography in detecting cardiac source of embolism in patients with cerebral ischemia of uncertain etiology | Q41837739 | ||
| Effects of amiodarone and diltiazem on persistent atrial fibrillation conversion and recurrence rates: a randomized controlled study | Q42171576 | ||
| Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy | Q42229679 | ||
| Ventricular fibrillation following verapamil in the Wolff-Parkinson-White syndrome | Q42260182 | ||
| Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure | Q42275725 | ||
| Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine Trial). | Q42277566 | ||
| Pregnancy outcome after gestational exposure to amiodarone in Canada | Q42278776 | ||
| Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Sotalol Multicenter Study Group | Q42281464 | ||
| Risk factors for intracranial hemorrhage in outpatients taking warfarin | Q42285556 | ||
| Amiodarone in restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation after unsuccessful direct-current cardioversion. | Q42550249 | ||
| Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators | Q42550740 | ||
| Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators | Q42551004 | ||
| European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke | Q42551725 | ||
| Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group | Q42553509 | ||
| Comparisons of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: a double-blind, randomized trial | Q42554542 | ||
| Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group | Q42556865 | ||
| Alpha-receptor restriction of coronary blood flow during atrial fibrillation | Q42665609 | ||
| Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial | Q42679144 | ||
| Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens | Q42691907 | ||
| Prognostic implications of left atrial spontaneous echo contrast in nonvalvular atrial fibrillation | Q43419712 | ||
| Long-term prognosis of patients with paroxysmal atrial fibrillation complicating acute myocardial infarction. SPRINT Study Group | Q43443801 | ||
| Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program | Q43446897 | ||
| Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions | Q43472007 | ||
| Thromboembolism in chronic atrial flutter: is the risk underestimated? | Q43478232 | ||
| Frequency and significance of cardiac arrhythmias in chronic obstructive lung disease | Q43491579 | ||
| Analysis of risk factors involved in oral-anticoagulant-related intracranial haemorrhages | Q43505750 | ||
| Clinical course of hypertrophic cardiomyopathy in a regional United States cohort | Q43565120 | ||
| Increased dispersion and shortened refractoriness caused by verapamil in chronic atrial fibrillation | Q43573547 | ||
| Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation | Q43603177 | ||
| Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial | Q43610373 | ||
| Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin | Q33671179 | ||
| Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis | Q33744558 | ||
| Pharmacologic versus direct-current electrical cardioversion of atrial flutter and fibrillation | Q33777328 | ||
| Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention | Q33781871 | ||
| Echocardiographic assessment of the left atrial appendage | Q33788498 | ||
| Current perspectives on statins | Q33818381 | ||
| Classification system of atrial fibrillation | Q33833107 | ||
| Intravenous amiodarone for the prevention of atrial fibrillation after open heart surgery: the Amiodarone Reduction in Coronary Heart (ARCH) trial | Q33870278 | ||
| Management of atrial fibrillation: therapeutic options and clinical decisions | Q33902710 | ||
| Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy | Q33924902 | ||
| Fish intake and risk of incident atrial fibrillation | Q33947310 | ||
| Effect of carvedilol on survival in severe chronic heart failure | Q33949292 | ||
| Spontaneous echo contrast: where there's smoke there's fire | Q34026438 | ||
| Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction | Q34051232 | ||
| Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The fiamingham Study | Q34054106 | ||
| Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). | Q34060107 | ||
| Hypertrophic cardiomyopathy: a systematic review | Q34117625 | ||
| Fibrosis and hypertensive heart disease | Q34119071 | ||
| Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety | Q34131082 | ||
| Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation | Q34154414 | ||
| A comparison of rate control and rhythm control in patients with atrial fibrillation | Q34162727 | ||
| Left Atrial Appendage Occlusion Study (LAAOS): a randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention | Q34168854 | ||
| Spontaneous echo contrast videodensity is flow-related and is dependent on the relative concentrations of fibrinogen and red blood cells | Q34178927 | ||
| The natural history of lone atrial fibrillation. A population-based study over three decades | Q34186025 | ||
| Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study | Q34186228 | ||
| Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study | Q34201000 | ||
| Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial | Q34213067 | ||
| A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study | Q34225539 | ||
| Meta-analysis of the effectiveness of prophylactic drug therapy in preventing supraventricular arrhythmia early after coronary artery bypass grafting | Q34242357 | ||
| A Classification of Antiarrhythmic Actions Reassessed After a Decade of New Drugs | Q34248170 | ||
| Thoracoscopic extracardiac obliteration of the left atrial appendage for stroke risk reduction in atrial fibrillation | Q34266837 | ||
| Rising rates of hospital admissions for atrial fibrillation. | Q34271333 | ||
| Beneficial cardiovascular pleiotropic effects of statins | Q34327115 | ||
| Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial | Q44672192 | ||
| Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study | Q44672306 | ||
| Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? | Q44684620 | ||
| Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial | Q44690382 | ||
| Effectiveness of oral propafenone for the prevention of atrial fibrillation after coronary artery bypass grafting | Q44700613 | ||
| Electrode pad size, transthoracic impedance and success of external ventricular defibrillation | Q44720235 | ||
| A randomized placebo-controlled trial of pre-treatment and short- or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation | Q44726808 | ||
| Quality of life variables in the selection of rate versus rhythm control in patients with atrial fibrillation: observations from the Canadian Trial of Atrial Fibrillation | Q44739491 | ||
| Atrial fibrillation originating from persistent left superior vena cava | Q44752432 | ||
| N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. | Q44754719 | ||
| Long-term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation: amiodarone vs propafenone, both in low doses | Q44760400 | ||
| Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification | Q44766898 | ||
| Postoperative atrial fibrillation and mortality after coronary artery bypass surgery | Q44785079 | ||
| Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries | Q44789624 | ||
| Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study | Q44790546 | ||
| Effects of pretreatment with intravenous flecainide on efficacy of external cardioversion of persistent atrial fibrillation | Q44792464 | ||
| The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model | Q44801115 | ||
| Racial variation in the prevalence of atrial fibrillation among patients with heart failure: the Epidemiology, Practice, Outcomes, and Costs of Heart Failure (EPOCH) study | Q44815608 | ||
| The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial | Q44829218 | ||
| Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. | Q44855885 | ||
| Early recurrence of arrhythmia in patients taking amiodarone or class 1C agents for treatment of atrial fibrillation or atrial flutter | Q44862922 | ||
| A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate | Q44917498 | ||
| Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction | Q44938331 | ||
| Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter | Q44964089 | ||
| Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial | Q45012060 | ||
| Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study | Q45012571 | ||
| Ibutilide added to propafenone for the conversion of atrial fibrillation and atrial flutter. | Q45019439 | ||
| Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents | Q45019442 | ||
| Suppression of paroxysmal atrial tachyarrhythmias--results of the SOPAT trial | Q45024771 | ||
| Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. | Q45032662 | ||
| Comparative effects of carvedilol and amiodarone on conversion and recurrence rates of persistent atrial fibrillation | Q45040786 | ||
| "Early" class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat | Q45057043 | ||
| Conversion of atrial flutter by ibutilide is associated with increased atrial cycle length variability | Q45096247 | ||
| Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs | Q45101331 | ||
| Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study | Q45104281 | ||
| Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias | Q45110333 | ||
| Increased myocardial collagen content in transgenic rats overexpressing cardiac angiotensin-converting enzyme is related to enhanced breakdown of N-acetyl-Ser-Asp-Lys-Pro and increased phosphorylation of Smad2/3. | Q45134127 | ||
| Presence of left-to-right atrial frequency gradient in paroxysmal but not persistent atrial fibrillation in humans | Q45144403 | ||
| Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach | Q45170339 | ||
| Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation | Q45209467 | ||
| Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial | Q45258336 | ||
| Ximelagatran--promises and concerns | Q45258342 | ||
| Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial | Q45263385 | ||
| Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study | Q45285130 | ||
| Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study | Q45285131 | ||
| A new pacemaker algorithm for the treatment of atrial fibrillation: results of the Atrial Dynamic Overdrive Pacing Trial (ADOPT). | Q45972950 | ||
| Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. | Q45985183 | ||
| Factor V Leiden and risk of ischemic stroke in nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study | Q46136302 | ||
| Risk of thromboembolism in chronic atrial flutter | Q46185719 | ||
| Pregnancy and its outcome in women with and without surgical treatment of congenital heart disease | Q46382559 | ||
| Electrophysiologic and electroanatomic changes in the human atrium associated with age. | Q51995097 | ||
| Efficacy of biphasic shock for transthoracic cardioversion of persistent atrial fibrillation: can we predict energy requirements? | Q51996344 | ||
| Left atrial size and function after spontaneous cardioversion of atrial fibrillation and their relation to N-terminal atrial natriuretic peptide. | Q52014230 | ||
| Randomized crossover comparison of right atrial appendage pacing versus interatrial septum pacing for prevention of paroxysmal atrial fibrillation in patients with sinus bradycardia. | Q52051380 | ||
| Safety and feasibility of a novel rate-smoothed ventricular pacing algorithm for atrial fibrillation. | Q52058022 | ||
| Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation. ELAT Study Group. Embolism in Left Atrial Thrombi. | Q52229885 | ||
| Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study. | Q52342463 | ||
| Diurnal variation of ventricular response to atrial fibrillation in patients with advanced heart failure. | Q52358900 | ||
| Myocardial cell death in fibrillating and dilated human right atria. | Q52536924 | ||
| Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. | Q52880775 | ||
| Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: characterization by simultaneous transesophageal echocardiography. | Q52884209 | ||
| Left atrial spontaneous echo contrast in patients with rheumatic mitral valve stenosis in sinus rhythm: relationship to mitral valve and left atrial measurements. | Q52927564 | ||
| Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. | Q53295361 | ||
| Catheter ablation for atrial fibrillation in congestive heart failure. | Q53317630 | ||
| Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. | Q53340933 | ||
| Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. | Q53347408 | ||
| Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. | Q53358007 | ||
| Cardiac resynchronization in patients with congestive heart failure and chronic atrial fibrillation: effect of upgrading to biventricular pacing after chronic right ventricular pacing. | Q53440902 | ||
| AV node ablation and pacemaker implantation after withdrawal of effective rate-control medications for chronic atrial fibrillation: effect on quality of life and exercise performance. | Q53535644 | ||
| Effects of radiofrequency catheter ablation on quality of life in patients with atrial flutter. | Q53541201 | ||
| Design and implementation of the Dual Site Atrial Pacing to Prevent Atrial Fibrillation (DAPPAF) clinical trial. DAPPAF Phase 1 Investigators. | Q53563654 | ||
| The Ablate and Pace Trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. APT Investigators. | Q53563663 | ||
| Quality of life and clinical outcomes in elderly patients treated with ventricular pacing as compared with dual-chamber pacing. Pacemaker Selection in the Elderly Investigators. | Q53580310 | ||
| Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia. | Q53656499 | ||
| Reverse structural and gap-junctional remodeling after prolonged atrial fibrillation in the goat. | Q53738442 | ||
| Oral d,l sotalol reduces the incidence of postoperative atrial fibrillation in coronary artery bypass surgery patients: a randomized, double-blind, placebo-controlled study. | Q53927223 | ||
| Electrical activity of the pulmonary vein and its interaction with the right atrium in the guinea‐pig | Q53947656 | ||
| Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. | Q54092181 | ||
| Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. | Q54114563 | ||
| Beta-adrenergic blockade accelerates conversion of postoperative supraventricular tachyarrhythmias. | Q54116167 | ||
| Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study. | Q54126951 | ||
| Echocardiographic diastolic ventricular abnormality in hypertensive heart disease: atrial emptying index. | Q54536298 | ||
| Spread of excitation from the atrium into thoracic veins in human beings and dogs | Q54544168 | ||
| Arrhythmias associated with acute respiratory failure in patients with chronic airway obstruction. | Q54620403 | ||
| Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: The stroke prevention in atrial fibrillation study. | Q54704985 | ||
| A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. | Q55036185 | ||
| Extended distribution of prolonged and fractionated right atrial electrograms predicts development of chronic atrial fibrillation in patients with idiopathic paroxysmal atrial fibrillation. | Q55036219 | ||
| Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial | Q56659254 | ||
| Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines a | Q56987002 | ||
| Obesity and the Risk of New-Onset Atrial Fibrillation | Q57073134 | ||
| Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality | Q57073207 | ||
| Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by radiofrequency current | Q57223785 | ||
| Trends in hospital activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986–1996 | Q57396385 | ||
| Atrial fibrillation as a self-sustaining arrhythmia independent of focal discharge | Q57480466 | ||
| Improving survival for patients with atrial fibrillation and advanced heart failure | Q57631087 | ||
| Left Atrial-Esophageal Fistula Following Radiofrequency Catheter Ablation of Atrial Fibrillation | Q58757654 | ||
| Increased Intensity of Anticoagulation May Reduce Risk of Thrombus During Atrial Fibrillation Ablation Procedures in Patients with Spontaneous Echo Contrast | Q58815151 | ||
| A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm | Q58819305 | ||
| Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment | Q70412437 | ||
| Cardioversion of atrial fibrillation: consideration of embolization, anticoagulation, prophylactic pacemaker, and long-term success | Q70443039 | ||
| Electrical properties of the thoracic veins | Q70452259 | ||
| Comparison of flecainide and procainamide in cardioversion of atrial fibrillation | Q70493406 | ||
| Hematologic correlates of left atrial spontaneous echo contrast and thromboembolism in nonvalvular atrial fibrillation | Q70543019 | ||
| Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi | Q70570906 | ||
| Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation | Q70573988 | ||
| Recurrence of paroxysmal atrial fibrillation or flutter after successful cardioversion in patients with normal left ventricular function | Q70595101 | ||
| Significant mitral regurgitation is protective against left atrial spontaneous echo contrast and thrombus as assessed by transesophageal echocardiography | Q70678203 | ||
| The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Amiodarone vs quinidine for conversion of atrial fibrillation | Q70799876 | ||
| Arterial embolism in thyrotoxicosis with atrial fibrillation | Q70862982 | ||
| Controlled trial of a long-acting quinidine for maintenance of sinus rhythm after conversion of sustained atrial fibrillation | Q70906358 | ||
| Effectiveness of intravenous propafenone for conversion of recent-onset atrial fibrillation: a placebo-controlled study | Q70975003 | ||
| Safety of Electrical Cardioversion in Patients Without Digitalis Toxicity | Q70993956 | ||
| Effect of continuous vagal enhancement on concealed conduction and refractoriness within the atrioventricular node | Q71015645 | ||
| Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study | Q71020117 | ||
| The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics | Q71064706 | ||
| Transesophageal echocardiographic evaluation of left atrial appendage function and spontaneous contrast formation after chemical or electrical cardioversion of atrial fibrillation | Q71381974 | ||
| Effects of propranolol and of verapamil on heart rate and blood pressure in hyperthyroidism | Q71388646 | ||
| Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study | Q71442263 | ||
| The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life | Q71493673 | ||
| Prevalence of residual left atrial thrombi among patients with acute thromboembolism and newly recognized atrial fibrillation | Q71558183 | ||
| Antiarrhythmic effect of converting enzyme inhibitors in congestive heart failure | Q71623329 | ||
| Initial experience with intracardiac atrial defibrillation in patients with chronic atrial fibrillation | Q71634799 | ||
| Variability of the ventricular response in atrial fibrillation and prognosis in chronic nonischemic mitral regurgitation | Q71659267 | ||
| Thromboembolism following cardioversion of "common" atrial flutter. Risk factors and limitations of transesophageal echocardiography | Q71692578 | ||
| How useful is thyroid function testing in patients with recent-onset atrial fibrillation? The Canadian Registry of Atrial Fibrillation Investigators | Q71714531 | ||
| Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine | Q71745694 | ||
| Treatment of arrhythmias during pregnancy | Q71774260 | ||
| Efficacy and safety of procainamide in preventing arrhythmias after coronary artery bypass surgery | Q71774893 | ||
| The hemodynamic consequences of cardiac arrhythmias: evaluation of the relative roles of abnormal atrioventricular sequencing, irregularity of ventricular rhythm and atrial fibrillation in a canine model | Q71782637 | ||
| Coronary heart disease and atrial fibrillation: the Framingham Study | Q71782665 | ||
| Chemical cardioversion of atrial fibrillation with intravenous dofetilide | Q71941423 | ||
| Propafenone for conversion of recent-onset atrial fibrillation. A controlled comparison between oral loading dose and intravenous administration | Q71956990 | ||
| Modification of the maze procedure for atrial flutter and atrial fibrillation. I. Rationale and surgical results | Q71964521 | ||
| Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation | Q71975694 | ||
| Coagulation activity is increased in the left atrium of patients with mitral stenosis | Q71987768 | ||
| Atrial fibrillation and arterial embolism in hyperthyroidism | Q72024979 | ||
| Significant mitral regurgitation is protective against left atrial spontaneous echo contrast formation, but not against systemic embolism | Q72035415 | ||
| Mechanism of atrial fibrillation and increased incidence of thromboembolism in patients with hypertrophic cardiomyopathy | Q72038987 | ||
| Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study | Q72051686 | ||
| Relation of left atrial pathology to atrial fibrillation in mitral valvular disease | Q72063759 | ||
| Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide | Q72065779 | ||
| Analysis of vagal effects on ventricular rhythm in patients with atrial fibrillation | Q72066061 | ||
| Direct current countershock complications | Q72170753 | ||
| Transesophageal echocardiographic determinants of embolism in nonrheumatic atrial fibrillation | Q72191797 | ||
| Relation of left atrial appendage function to the duration and reversibility of nonvalvular atrial fibrillation | Q72198082 | ||
| The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study | Q72198409 | ||
| Human experience with amiodarone in the embryonic period | Q72207299 | ||
| Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo | Q72238587 | ||
| High dose oral amiodarone loading exerts important hemodynamic actions in patients with congestive heart failure | Q72255362 | ||
| Clinical course of recent-onset atrial fibrillation treated with oral propafenone | Q72374285 | ||
| Efficacy of flecainide in patients with supraventricular arrhythmias and respiratory insufficiency | Q72376882 | ||
| Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study | Q72429317 | ||
| Transthoracic echo/Doppler in the identification of patients with chronic non-valvular atrial fibrillation at risk for thromboembolic events | Q72459356 | ||
| Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation | Q72468018 | ||
| Controlled trial of sotalol for one year after myocardial infarction | Q72526496 | ||
| Radiofrequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation | Q72526986 | ||
| Mitral regurgitation associated with reduced thromboembolic events in high-risk patients with nonrheumatic atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators | Q72541189 | ||
| Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications | Q72566134 | ||
| Cardioversion and Digitalis Drugs: Changed Threshold to Electric Shock in Digitalized Animals | Q72592046 | ||
| Temporal dependence of the return of atrial mechanical function on the mode of cardioversion of atrial fibrillation to sinus rhythm | Q72623691 | ||
| Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation | Q72655008 | ||
| Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for "atrial stunning" as a mechanism of thromboembolic complications | Q72740780 | ||
| Clinical implications and factors related to left atrial spontaneous echo contrast in chronic nonvalvular atrial fibrillation | Q72790205 | ||
| Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease | Q72906519 | ||
| Effectiveness and costs of digoxin treatment for atrial fibrillation and flutter | Q72906522 | ||
| Hazards of postoperative atrial arrhythmias | Q72939296 | ||
| Predictors of left atrial spontaneous echo contrast and thrombi in patients with mitral stenosis and atrial fibrillation | Q73014666 | ||
| Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators | Q73028209 | ||
| Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone | Q73048675 | ||
| Cardioversion guided by transesophageal echocardiography: the ACUTE Pilot Study. A randomized, controlled trial. Assessment of Cardioversion Using Transesophageal Echocardiography | Q73055216 | ||
| Mechanism of flutter and fibrillation | Q73087245 | ||
| Prevalence and clinical significance of left atrial thrombus in nonrheumatic atrial fibrillation | Q73108707 | ||
| Reversal of atrial electrical remodeling following cardioversion of long-standing atrial fibrillation in man | Q73112802 | ||
| Plasma cardiac natriuretic peptides as biochemical markers of recurrence of atrial fibrillation in patients with mild congestive heart failure | Q73143847 | ||
| Atrial fibrillation induced by atrioventricular nodal reentrant tachycardia | Q73151553 | ||
| Electrocardiographic differentiation of atrial flutter from atrial fibrillation by physicians | Q73152794 | ||
| Prospective assessment of the minimum energy needed for external electrical cardioversion of atrial fibrillation | Q73155629 | ||
| Selective atrionodal input ablation for induction of proximal complete heart block with stable junctional escape rhythm in patients with uncontrolled atrial fibrillation | Q73161402 | ||
| A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial | Q73180786 | ||
| Multicenter low energy transvenous atrial defibrillation (XAD) trial results in different subsets of atrial fibrillation | Q73199245 | ||
| Comparison of oral loading dose of propafenone and amiodarone for converting recent-onset atrial fibrillation. PARSIFAL Study Group | Q73200648 | ||
| Pulsed Doppler evaluation of atrial mechanical function after electrical cardioversion of atrial fibrillation | Q69948977 | ||
| Transesophageal two-dimensional echocardiography for the detection of left atrial appendage thrombus | Q69990661 | ||
| Amiodarone for refractory atrial fibrillation | Q69992187 | ||
| Effect of enalapril on ventricular arrhythmias in congestive heart failure | Q70099437 | ||
| The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation | Q70105143 | ||
| Epidemiologic features of chronic atrial fibrillation: the Framingham study | Q70294399 | ||
| Successful use of flecainide in atrial fibrillation with rapid ventricular rate in the Wolff-Parkinson-White syndrome | Q70390804 | ||
| Treatment of atrial tachyarrhythmias and preexcitation syndrome with flecainide acetate | Q70399665 | ||
| Transesophageal echocardiographic evidence of more pronounced left atrial stunning after chemical (propafenone) rather than electrical attempts at cardioversion from atrial fibrillation | Q73200712 | ||
| Effect of verapamil on immediate recurrence of atrial fibrillation | Q73202356 | ||
| Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study | Q73218242 | ||
| Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized, controlled trial | Q73223941 | ||
| Comparisons of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation | Q73227469 | ||
| Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study) | Q73251324 | ||
| Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: II. Dense spontaneous echocardiographic contrast (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study) | Q73251328 | ||
| Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias | Q73280896 | ||
| Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group | Q73294357 | ||
| Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies | Q73341261 | ||
| Stable microreentrant sources as a mechanism of atrial fibrillation in the isolated sheep heart | Q73358623 | ||
| Serum troponins T and I after elective cardioversion | Q73365063 | ||
| Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial | Q73365342 | ||
| Is there a place for the late cardioversion of atrial fibrillation? A long-term follow-up study of patients with post-thyrotoxic atrial fibrillation | Q73399247 | ||
| Risk of stroke in patients with atrial flutter | Q73412509 | ||
| Relation of age and sex to atrial electrophysiological properties in patients with no history of atrial fibrillation | Q73434708 | ||
| Prediction of paroxysmal atrial fibrillation in patients with congestive heart failure: a prospective study | Q73453220 | ||
| Locus for atrial fibrillation maps to chromosome 6q14-16 | Q73469209 | ||
| Atrial flutter: 1 to 1 conduction during treatment with quinidine and digitalis | Q73522333 | ||
| Effectiveness of amiodarone as a single oral dose for recent-onset atrial fibrillation | Q73574876 | ||
| Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators | Q73594702 | ||
| Effects of lisinopril in patients with heart failure and chronic atrial fibrillation | Q73597621 | ||
| Significant effects of atrioventricular node ablation and pacemaker implantation on left ventricular function and long-term survival in patients with atrial fibrillation and left ventricular dysfunction | Q73614926 | ||
| Unmasking effect of propafenone on the concealed form of the Brugada phenomenon | Q73631782 | ||
| Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study | Q73662522 | ||
| Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter | Q73665626 | ||
| Adverse effects of low dose amiodarone: a meta-analysis | Q73665648 | ||
| Quinidine versus propafenone for conversion of atrial fibrillation to sinus rhythm | Q73670439 | ||
| Clinical outcome of patients who develop PAF after CABG surgery | Q73676413 | ||
| Role of autonomic tone in the initiation and termination of paroxysmal atrial fibrillation in patients without structural heart disease | Q73698440 | ||
| Clinical study to investigate the predictive parameters for the onset of atrial fibrillation in patients with essential hypertension | Q73716478 | ||
| Fluctuation in autonomic tone is a major determinant of sustained atrial arrhythmias in patients with focal ectopy originating from the pulmonary veins | Q73731826 | ||
| Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation | Q73746106 | ||
| Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation | Q73782374 | ||
| Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Results of a randomized, double-blind, controlled study | Q73825465 | ||
| Internal atrial defibrillation: effect on sinus and atrioventricular nodal function and implanted cardiac pacemakers | Q73849470 | ||
| Prolonged fractionation of paced right atrial electrograms in patients with atrial flutter and fibrillation | Q73856239 | ||
| Reentrant tachycardia in pulmonary veins of patients with paroxysmal atrial fibrillation | Q73888945 | ||
| Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study | Q73905733 | ||
| Electrical remodeling of the human atrium: similar effects in patients with chronic atrial fibrillation and atrial flutter | Q73914295 | ||
| Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery | Q73943609 | ||
| Initiation of atrial fibrillation by ectopic beats originating from the superior vena cava: electrophysiological characteristics and results of radiofrequency ablation | Q73954430 | ||
| Atrial natriuretic peptide level after cardioversion of chronic atrial fibrillation | Q74084648 | ||
| Initial energy for elective external cardioversion of persistent atrial fibrillation | Q74099048 | ||
| Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure | Q74104662 | ||
| Cardioversion of atrial fibrillation in the setting of mild to moderate heart failure | Q74242009 | ||
| Effects of diltiazem pretreatment on direct-current cardioversion in patients with persistent atrial fibrillation: a single-blind, randomized, controlled study | Q74246245 | ||
| Autonomic tone variations before the onset of paroxysmal atrial fibrillation | Q74268938 | ||
| Biatrial multisite mapping of atrial premature complexes triggering onset of atrial fibrillation | Q74293176 | ||
| Ventricular pacing or dual-chamber pacing for sinus-node dysfunction | Q74294883 | ||
| Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators | Q74315489 | ||
| Immediate reinitiation of atrial fibrillation following internal atrial defibrillation | Q74343094 | ||
| Prevention of chronic atrial fibrillation by pacing in the region of Bachmann's bundle: results of a multicenter randomized trial | Q74401505 | ||
| Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria | Q74439046 | ||
| Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation | Q74530522 | ||
| Left atrial appendage function assessed by transesophageal echocardiography before and on the day after elective cardioversion for nonvalvular atrial fibrillation | Q74596983 | ||
| Mechanical dysfunction of the left atrium and the left atrial appendage following cardioversion of atrial fibrillation and its relation to total electrical energy used for cardioversion | Q74597233 | ||
| Efficacy of amiodarone for the termination of persistent atrial fibrillation | Q74598122 | ||
| Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators | Q74648389 | ||
| Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials | Q74725371 | ||
| Effect of electrode length on atrial defibrillation thresholds | Q74756862 | ||
| Cost of care distribution in atrial fibrillation patients: the COCAF study | Q75202014 | ||
| Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation | Q75296207 | ||
| Acute comparative effect of right and left ventricular pacing in patients with permanent atrial fibrillation | Q75310290 | ||
| Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin | Q76340017 | ||
| Rate versus rhythm control in atrial fibrillation | Q76395949 | ||
| OBSERVATIONS ON THE VENTRICULAR DYSRHYTHMIA ASSOCIATED WITH ATRIAL FIBRILLATION IN THE DOG HEART | Q76832113 | ||
| COMPLICATIONS AND LIMITATIONS OF DIRECT-CURRENT COUNTERSHOCK | Q76924425 | ||
| Dispersion of atrial repolarization in patients with paroxysmal atrial fibrillation | Q77065895 | ||
| Left atrial "stunning" following radiofrequency catheter ablation of chronic atrial flutter | Q77107608 | ||
| Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation | Q77178177 | ||
| Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left V | Q77313148 | ||
| Right atrial focal atrial fibrillation: electrophysiologic characteristics and radiofrequency catheter ablation | Q77347251 | ||
| Power spectral analysis of heart period variability of preceding sinus rhythm before initiation of paroxysmal atrial fibrillation | Q77442972 | ||
| Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology | Q77476602 | ||
| Atrial mechanical performance following internal and external cardioversion of atrial fibrillation: its relationship to peripheral embolization and acute cerebrovascular accident | Q77504405 | ||
| Different patterns of angiotensin II and atrial natriuretic peptide secretion in a sheep model of atrial fibrillation | Q77509323 | ||
| Lengthening of intraatrial conduction time in atrial fibrillation and its relation with early recurrence of atrial fibrillation | Q77529457 | ||
| Long-term outcome of patients with drug-refractory atrial flutter and fibrillation after single- and dual-site right atrial pacing for arrhythmia prevention | Q77700068 | ||
| Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis | Q77750586 | ||
| The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution | Q77753528 | ||
| Atrial fibrillation in endomyocardial fibrosis is a marker of worse prognosis | Q77764718 | ||
| Paroxysmal cycle length shortening in the pulmonary veins during atrial fibrillation correlates with arrhythmogenic triggering foci in sinus rhythm | Q77784023 | ||
| Analysis of heart rate variability five minutes before the onset of paroxysmal atrial fibrillation | Q77826431 | ||
| Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group | Q77933868 | ||
| The role of oral 1C antiarrhythmic drugs in terminating atrial fibrillation | Q77949286 | ||
| Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort | Q77960625 | ||
| Effect of intravenous magnesium on heart rate and heart rate variability in patients with chronic atrial fibrillation | Q77997721 | ||
| Transient proarrhythmic state following atrioventricular junctional radiofrequency ablation | Q78046461 | ||
| Prevention of postoperative atrial fibrillation: what is the best approach? | Q78106138 | ||
| Evaluation of biatrial pacing, right atrial pacing, and no pacing in patients with drug refractory atrial fibrillation | Q78194788 | ||
| Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion | Q78251235 | ||
| Improved suppression of recurrent atrial fibrillation with dual-site right atrial pacing and antiarrhythmic drug therapy | Q78298429 | ||
| Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors | Q78346363 | ||
| Distinctive electrophysiological properties of pulmonary veins in patients with atrial fibrillation | Q78477511 | ||
| Detection and characterization of intracardiac thrombi on MR imaging | Q78532327 | ||
| A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation | Q78613787 | ||
| Monitoring the progression of the atrial electrical remodeling in patients with paroxysmal atrial fibrillation | Q78841329 | ||
| Obliteration of the left atrial appendage for prevention of thromboembolism | Q79106873 | ||
| Autonomic modulation preceding the onset of atrial fibrillation | Q79106875 | ||
| Catheter ablation for paroxysmal atrial fibrillation: segmental pulmonary vein ostial ablation versus left atrial ablation | Q79161359 | ||
| Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion | Q79322759 | ||
| Sex-specific increase in the prevalence of atrial fibrillation (The Copenhagen City Heart Study) | Q79366756 | ||
| "Cardioversion" of atrial fibrillation. A report on the treatment of 65 episodes in 50 patients | Q79443159 | ||
| Left ventricular mechanics during right ventricular apical or left ventricular-based pacing in patients with chronic atrial fibrillation after atrioventricular junction ablation | Q79792540 | ||
| Percutaneous left atrial appendage transcatheter occlusion: an effective and safe protection against stroke or embolism? | Q79797276 | ||
| Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillation | Q80060740 | ||
| Reversal of electrical remodeling after cardioversion of persistent atrial fibrillation | Q80101026 | ||
| Common left pulmonary vein: a consistent source of arrhythmogenic atrial ectopy | Q80101143 | ||
| A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension | Q35179552 | ||
| Beta-blocker therapy in atrial fibrillation | Q35197755 | ||
| Recent advances in drug therapy for atrial fibrillation | Q35209693 | ||
| Atrioventricular nodal ablation and implantation of mode switching dual chamber pacemakers: effective treatment for drug refractory paroxysmal atrial fibrillation | Q35367994 | ||
| An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. | Q35373386 | ||
| External cardioversion of atrial fibrillation: role of paddle position on technical efficacy and energy requirements | Q35374188 | ||
| Lack of prevention of heart failure by serial electrical cardioversion in patients with persistent atrial fibrillation | Q35565932 | ||
| Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study | Q35567061 | ||
| Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK | Q35582163 | ||
| Atrial fibrillation after radiofrequency ablation of atrial flutter: preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics | Q35582807 | ||
| Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation | Q35582996 | ||
| Predicting the risk of atrial fibrillation after coronary artery bypass surgery | Q35605200 | ||
| Atrial pacing for the prevention of atrial fibrillation after coronary artery bypass graft surgery: a review of the literature | Q35632146 | ||
| Pharmacological rate control of atrial fibrillation | Q35680137 | ||
| Advances in the surgical treatment of atrial fibrillation | Q35680154 | ||
| Progress in nonpharmacologic therapy of atrial fibrillation | Q35684059 | ||
| Pharmacology of cardiac potassium channels. | Q35692275 | ||
| Cardiac surgery for arrhythmias | Q35694525 | ||
| Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study | Q35722724 | ||
| Female preponderance in ibutilide-induced torsade de pointes | Q35802936 | ||
| Echocardiographic evaluation of cardiac resynchronization therapy: ready for routine clinical use? A critical appraisal | Q35826854 | ||
| Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy | Q35895172 | ||
| Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter | Q35902898 | ||
| Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? | Q35954331 | ||
| Techniques for curative treatment of atrial fibrillation | Q35989523 | ||
| Role of permanent pacing to prevent atrial fibrillation: science advisory from the American Heart Association Council on Clinical Cardiology (Subcommittee on Electrocardiography and Arrhythmias) and the Quality of Care and Outcomes Research Interdis | Q36013115 | ||
| Alterations in atrial electrophysiology and tissue structure in a canine model of chronic atrial dilatation due to mitral regurgitation | Q36016921 | ||
| Outcomes of radiofrequency catheter ablation of atrioventricular reciprocating tachycardia in patients with congenital heart disease | Q36105994 | ||
| Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study | Q36255692 | ||
| Rate versus rhythm control in the management of patients with atrial fibrillation | Q36269171 | ||
| Left atrial spontaneous echo contrast in mitral valve disease: an indicator for an increased thromboembolic risk | Q36421264 | ||
| Assessment of left atrial appendage function by biplane transesophageal echocardiography in patients with nonrheumatic atrial fibrillation: identification of a subgroup of patients at increased embolic risk | Q36742857 | ||
| Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter. A multicentre study from Stockholm | Q36788538 | ||
| Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation | Q36843189 | ||
| Atrio-esophageal fistula as a complication of percutaneous transcatheter ablation of atrial fibrillation | Q80123638 | ||
| Beta-blockers prevent subacute recurrences of persistent atrial fibrillation only in patients with hypertension | Q80150455 | ||
| Comparison of the rectilinear biphasic waveform with the monophasic damped sine waveform for external cardioversion of atrial fibrillation and flutter | Q80193927 | ||
| Autonomic nervous system and paroxysmal atrial fibrillation: a study based on the analysis of RR interval changes before, during and after paroxysmal atrial fibrillation | Q80322223 | ||
| Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence | Q80357422 | ||
| Left atrial tachycardia after circumferential pulmonary vein ablation for atrial fibrillation: electroanatomic characterization and treatment | Q80507992 | ||
| Relation of C-reactive protein correlates with risk of thromboembolism in patients with atrial fibrillation | Q80579406 | ||
| The who, what, why, and how-to guide for circumferential pulmonary vein ablation | Q80863855 | ||
| Prevention of iatrogenic atrial tachycardia after ablation of atrial fibrillation: a prospective randomized study comparing circumferential pulmonary vein ablation with a modified approach | Q80946114 | ||
| Obesity and atrial fibrillation: is one epidemic feeding the other? | Q81053239 | ||
| Pulmonary vein antrum isolation: intracardiac echocardiography-guided technique | Q81083923 | ||
| Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial | Q28193437 | ||
| Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial | Q28193553 | ||
| Warfarin, aspirin, or both after myocardial infarction | Q28193836 | ||
| Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis | Q28194233 | ||
| Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal | Q28195525 | ||
| A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin | Q28195787 | ||
| Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation | Q28196402 | ||
| Expression and activity of ectopeptidases in fibrillating human atria | Q28205443 | ||
| Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation | Q28210235 | ||
| Efficacy of anticoagulation for secondary stroke prevention in older people with non-valvular atrial fibrillation: a prospective case series study | Q28211632 | ||
| Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation | Q28237224 | ||
| Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care | Q28237957 | ||
| Auricular fibrillation with aberration simulating ventricular paroxysmal tachycardia | Q28276495 | ||
| Diet, lifestyle, and the etiology of coronary artery disease: the Cornell China study | Q28292020 | ||
| Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecainide | Q28333258 | ||
| Canine left ventricular hypertrophy predisposes to ventricular tachycardia induction by phase 2 early afterdepolarizations after administration of BAY K 8644 | Q28342680 | ||
| Extreme tachycardia complicating the use of disopyramide in atrial flutter | Q28367274 | ||
| Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group | Q28372836 | ||
| Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group | Q28373167 | ||
| Usefulness of ibutilide in facilitating successful external cardioversion of refractory atrial fibrillation | Q28376703 | ||
| Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) | Q28378044 | ||
| Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation | Q28378052 | ||
| Validation of Clinical Classification Schemes for Predicting Stroke | Q29028208 | ||
| Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study | Q29614197 | ||
| Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients | Q29619542 | ||
| Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins | Q29620720 | ||
| Efficacy and safety of moricizine in the maintenance of sinus rhythm in patients with recurrent atrial fibrillation | Q31817164 | ||
| Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation | Q32055123 | ||
| Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia | Q32055132 | ||
| Potential clinical efficacy and cost benefit of a transesophageal echocardiography-guided low-molecular-weight heparin (enoxaparin) approach to antithrombotic therapy in patients undergoing immediate cardioversion from atrial fibrillation | Q32157315 | ||
| Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management | Q33145671 | ||
| Cost effectiveness of inpatient initiation of antiarrhythmic therapy for supraventricular tachycardias | Q33175457 | ||
| Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin | Q33489438 | ||
| Sotalol: An important new antiarrhythmic | Q33536633 | ||
| What is meant by a "controlled" ventricular rate in atrial fibrillation? | Q33610558 | ||
| Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study) | Q81515045 | ||
| Role of transtelephonic electrocardiographic monitoring in detecting short-term arrhythmia recurrences after radiofrequency ablation in patients with atrial fibrillation | Q81520941 | ||
| Freedom from atrial tachyarrhythmias after catheter ablation of atrial fibrillation: a randomized comparison between 2 current ablation strategies | Q81802461 | ||
| Experimental studies on auricular flutter and auricular fibrillation | Q82392862 | ||
| A differential effect of aspirin on prevention of stroke in atrial fibrillation | Q86527103 | ||
| Evaluation of flecainide acetate in rapid atrial fibrillation complicating Wolff-Parkinson-White syndrome | Q93571413 | ||
| Monophasic action potential and sinus rhythm stability after conversion of atrial fibrillation | Q93722570 | ||
| Atrial ultrastructural changes during experimental atrial tachycardia depend on high ventricular rate | Q95823739 | ||
| Comparison of digoxin versus low-dose amiodarone for ventricular rate control in patients with chronic atrial fibrillation | Q43622845 | ||
| Focal atrial fibrillation: experimental evidence for a pathophysiologic role of the autonomic nervous system | Q43626176 | ||
| VERDICT: the Verapamil versus Digoxin Cardioversion Trial: A randomized study on the role of calcium lowering for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation | Q43685261 | ||
| Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol | Q43693918 | ||
| Beneficial effect of carvedilol on heart rate response to exercise in digitalised patients with heart failure in atrial fibrillation due to idiopathic dilated cardiomyopathy. | Q43711820 | ||
| Effect of diltiazem on the recurrence rate of paroxysmal atrial fibrillation | Q43720911 | ||
| Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program | Q43722328 | ||
| Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators | Q43764537 | ||
| Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation | Q43796173 | ||
| Risk factors for stroke in patients with nonrheumatic atrial fibrillation: a case-control study | Q43814544 | ||
| Flecainide acetate in the prevention of paroxysmal atrial fibrillation: a nine-month follow-up of more than 500 patients | Q43826181 | ||
| Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. | Q43841962 | ||
| C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation | Q43854958 | ||
| Comparison of Quality of Well-Being scale and NYHA functional status classification in patients with atrial fibrillation. New York Heart Association | Q43894595 | ||
| Efficacy of amiodarone for the termination of chronic atrial fibrillation and maintenance of normal sinus rhythm: a prospective, multicenter, randomized, controlled, double blind trial | Q43926578 | ||
| Canadian atrial fibrillation anticoaguiation (CAFA) study | Q43928649 | ||
| Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized, double-blinded trial | Q43969736 | ||
| Effect of acute atrial fibrillation on phasic coronary blood flow pattern and flow reserve in humans | Q43972052 | ||
| Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure | Q44025903 | ||
| Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. | Q44064962 | ||
| High energy transcatheter cardioversion of chronic atrial fibrillation | Q44073477 | ||
| Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. | Q44113840 | ||
| Comparison of verapamil and ibutilide for the suppression of immediate recurrences of atrial fibrillation after transthoracic cardioversion. | Q44136941 | ||
| Antiarrhythmic effects of intravenous timolol in supraventricular arrhythmias | Q44143465 | ||
| Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter | Q44145766 | ||
| The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation | Q44153210 | ||
| A Comparison of Intravenous Propafenone and Flecainide in the Treatment of Tachycardias Associated with the Wolff-Parkinson-White Syndrome | Q44234611 | ||
| Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study). | Q44247509 | ||
| Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction | Q44283425 | ||
| Electrophysiologic characterization of dronedarone in guinea pig ventricular cells | Q44291353 | ||
| Asymptomatic or "silent" atrial fibrillation: frequency in untreated patients and patients receiving azimilide | Q44342393 | ||
| Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone | Q44365422 | ||
| Pharmacological cardioversion of recent onset atrial fibrillation with intravenous amiodarone in patients receiving long-term amiodarone therapy: is it reasonable? | Q44372485 | ||
| Occurrence of Atrial Fibrillation in Patients With Paroxysmal Supraventricular Tachycardia Due to Atrioventricular Nodal Reentry | Q44406564 | ||
| Left atrial diameter in nonvalvular atrial fibrillation: An echocardiographic study. Stroke Prevention in Atrial Fibrillation Investigators | Q44411880 | ||
| Meta-analysis of antiarrhythmic therapy in the prevention of postoperative atrial fibrillation and the effect on hospital length of stay, costs, cerebrovascular accidents, and mortality in patients undergoing cardiac surgery | Q44416963 | ||
| Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy | Q44432066 | ||
| Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials | Q44456364 | ||
| The effect of atrial pacing therapies on atrial tachyarrhythmia burden and frequency: results of a randomized trial in patients with bradycardia and atrial tachyarrhythmias | Q44472974 | ||
| Safety and feasibility of a clinical pathway for the outpatient initiation of antiarrhythmic medications in patients with atrial fibrillation or atrial flutter | Q44476842 | ||
| Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation | Q44487854 | ||
| Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug | Q44505465 | ||
| VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study). | Q44543373 | ||
| Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study | Q44543376 | ||
| Safety and efficacy of in-office cardioversion for treatment of supraventricular arrhythmias | Q44546208 | ||
| Dronedarone for prevention of atrial fibrillation: a dose-ranging study. | Q44550267 | ||
| Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). | Q44567973 | ||
| Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials | Q44567980 | ||
| Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation | Q44616001 | ||
| Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation | Q44635360 | ||
| Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension | Q58819310 | ||
| Electrical Remodeling of the Atria in Congestive Heart Failure | Q58865426 | ||
| Pulmonary vein as an ectopic focus in digitalis-induced arrhythmia | Q59064425 | ||
| Genomic medicine and atrial fibrillation**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology | Q59461126 | ||
| Implications of Stroke Risk Criteria on the Anticoagulation Decision in Nonvalvular Atrial Fibrillation | Q59542153 | ||
| Efficacy of intravenous propafenone for the acute management of atrial fibrillation | Q61704179 | ||
| Incidence and clinical significance of ST segment elevation after electrical cardioversion of atrial fibrillation and atrial flutter | Q61965280 | ||
| Effects of flecainide on the atrial defibrillation threshold | Q61965303 | ||
| Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter | Q61965304 | ||
| Factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation. | Q64895943 | ||
| The use of quinidine in cardioversion. | Q64944894 | ||
| Intravenous propafenone in paroxysmal atrial fibrillation: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Paroxysmal Atrial Fibrillation Italian Trial (PAFIT)-2 Investigators. | Q67405710 | ||
| Effects of electrical countershock on serum creatine phosphokinase (CPK) isoenzyme activity | Q67432016 | ||
| Increase in radionuclide left ventricular ejection fraction after cardioversion of chronic atrial fibrillation in idiopathic dilated cardiomyopathy | Q67554308 | ||
| Coadministration of flecainide acetate and sotalol during pregnancy: Lack of teratogenic effects, passage across the placenta, and excretion in human breast milk | Q67654885 | ||
| Arterial embolism in thyrotoxicosis with atrial fibrillation | Q67673971 | ||
| Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators | Q67716302 | ||
| Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators | Q67716321 | ||
| The heart in hypertension | Q68035811 | ||
| Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation. The Sotalol Study Group | Q68058122 | ||
| Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up | Q68079912 | ||
| Stroke following coronary-artery bypass surgery. A case-control estimate of the risk from carotid bruits | Q68099251 | ||
| Amiodarone in the management of refractory atrial fibrillation | Q68186769 | ||
| Propafenone for paroxysmal atrial fibrillation | Q68263744 | ||
| Propafenone for prevention of recurrent atrial fibrillation | Q68304118 | ||
| The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm | Q68368848 | ||
| Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm | Q68495464 | ||
| Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation | Q68498046 | ||
| Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs | Q68709077 | ||
| Factors predisposing to supraventricular tachyarrhythmias after coronary artery bypass grafting | Q68804841 | ||
| Propafenone versus amiodarone in field treatment of primary atrial tachydysrhythmias | Q68811422 | ||
| Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil | Q68826784 | ||
| Increased intracardiovascular clotting in patients with chronic atrial fibrillation | Q68860554 | ||
| Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm | Q68899284 | ||
| Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm | Q69180959 | ||
| Mexiletine use in pregnancy and lactation | Q69190023 | ||
| Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium | Q69258719 | ||
| Myocardial release of hypoxanthine and lactate during percutaneous transluminal coronary angioplasty | Q69295329 | ||
| Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation | Q46466505 | ||
| Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). | Q46466522 | ||
| Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study | Q46505823 | ||
| Spectral analysis identifies sites of high-frequency activity maintaining atrial fibrillation in humans | Q46630207 | ||
| Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack | Q46686096 | ||
| Prophylaxis against postoperative atrial fibrillation: current progress and future directions | Q46870327 | ||
| Circumferential pulmonary-vein ablation for chronic atrial fibrillation | Q46971003 | ||
| Amyloid deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation. | Q47217880 | ||
| C-reactive protein and atrial fibrillation. Is inflammation a consequence or a cause of atrial fibrillation? | Q47230189 | ||
| Elective Cardioversion: Influence of Paddle-Electrode Location and Size on Success Rates and Energy Requirements | Q47278377 | ||
| The long-term outcome of patients with coronary disease and atrial fibrillation undergoing the Cox maze procedure | Q47304906 | ||
| Effect of sinus rhythm restoration on plasma brain natriuretic peptide in patients with atrial fibrillation | Q47354016 | ||
| Transthoracic impedance to defibrillator discharge. Effect of electrode size and electrode-chest wall interface | Q47370126 | ||
| Changes in left and right atrial size after cardioversion of atrial fibrillation: role of mitral valve disease | Q47384906 | ||
| Nonpulmonary vein foci: do they exist? | Q47695517 | ||
| Atrial fibrillation and hypercoagulability: dependent on clinical factors or/and on genetic alterations? | Q47754048 | ||
| Catheter ablation of paroxysmal atrial fibrillation initiated by non-pulmonary vein ectopy | Q47810712 | ||
| Antibodies against myosin in sera of patients with idiopathic paroxysmal atrial fibrillation | Q47880642 | ||
| Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women | Q47885299 | ||
| The Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial (AIRCRAFT). | Q47886162 | ||
| Multiplane transesophageal echocardiography: image orientation, examination technique, anatomic correlations, and clinical applications | Q47900235 | ||
| New Cryotechnology for Electrical Isolation of the Pulmonary Veins | Q47951284 | ||
| Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups | Q48090061 | ||
| Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Stroke Prevention in Atrial Fibrillation Investigators. | Q48362403 | ||
| Association of atrial fibrillation and obstructive sleep apnea | Q48587853 | ||
| Incidence of ischemic strokes in hypertrophic cardiomyopathy is markedly increased if complicated by atrial fibrillation | Q48647383 | ||
| Predictors of ischemic stroke in non-rheumatic atrial fibrillation. | Q48926108 | ||
| Pathogenesis of anterior circulation stroke in patients with nonvalvular atrial fibrillation: the Lausanne Stroke Registry. | Q48940188 | ||
| Variations of autonomic tone preceding onset of atrial fibrillation after coronary artery bypass grafting. | Q49089610 | ||
| Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo. | Q49094883 | ||
| Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. | Q49168469 | ||
| Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide Multicenter Study Group. | Q50545052 | ||
| Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group | Q50563525 | ||
| Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome. | Q50632243 | ||
| Recent trends in the incidence rates of and death rates from atrial fibrillation complicating initial acute myocardial infarction: a community-wide perspective. | Q50692137 | ||
| Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. | Q50723295 | ||
| Regular ventricular rhythms before conversion of recent onset atrial fibrillation to sinus rhythm. | Q50750535 | ||
| Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: comparison of two regimens. | Q50753311 | ||
| Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. | Q50861959 | ||
| Effects of caregiver specialty on cost and clinical outcomes following hospitalization for heart failure. | Q50875538 | ||
| Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis. | Q51021305 | ||
| Sinus pacemaker function after cardioversion of chronic atrial fibrillation: is sinus node remodeling related with recurrence? | Q51351930 | ||
| Efficacy and tolerability of transvenous low energy cardioversion of paroxysmal atrial fibrillation in humans. | Q51604516 | ||
| Effects of ventricular rate regularization pacing on quality of life and symptoms in patients with atrial fibrillation (Atrial fibrillation symptoms mediated by pacing to mean rates [AF SYMPTOMS study]). | Q51604663 | ||
| Atrial pacing for prevention of atrial fibrillation: assessment of simultaneously implemented algorithms. | Q51635807 | ||
| Mechanically induced potentials in atrial fibroblasts from rat hearts are sensitive to hypoxia/reoxygenation | Q51674342 | ||
| The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. | Q51693714 | ||
| The impact of atrial prevention and termination therapies on atrial tachyarrhythmia burden in patients receiving a dual-chamber defibrillator for ventricular arrhythmias. | Q51702884 | ||
| Combined efficacy of atrial septal lead placement and atrial pacing algorithms for prevention of paroxysmal atrial tachyarrhythmia. | Q51784009 | ||
| Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. | Q51995088 | ||
| The role of signal averaged P wave duration and serum magnesium as a combined predictor of atrial fibrillation after elective coronary artery bypass surgery | Q36844192 | ||
| Quinidine in maintenance of sinus rhythm after electroconversion of chronic atrial fibrillation. A controlled clinical study | Q36914538 | ||
| Value of quinidine in maintenance of sinus rhythm after electric conversion of atrial fibrillation | Q36916248 | ||
| Maintenance of sinus rhythm after DC reversion of atrial fibrilllation. A double-blind controlled trial of long-acting quinidine bisulphate | Q36917845 | ||
| Oral anticoagulant drugs | Q37003395 | ||
| Local stress, not systemic factors, regulate gene expression of the cardiac renin-angiotensin system in vivo: a comprehensive study of all its components in the dog. | Q37308105 | ||
| The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis | Q37333837 | ||
| Factors affecting cardioversion of atrial arrhythmias with special reference to quinidine | Q37487712 | ||
| Long-term results of DC reversion of atrial fibrillation | Q37487751 | ||
| Effect of right ventricular pacing on ventricular rhythm during atrial fibrillation | Q38185102 | ||
| Prophylactic Oral Amiodarone for the Prevention of Arrhythmias that Begin Early After Revascularization, Valve Replacement, or Repair: PAPABEAR: a randomized controlled trial | Q38410321 | ||
| Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study | Q38482974 | ||
| The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades | Q38483232 | ||
| Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: a community-wide perspective | Q38516208 | ||
| A prospective, single-center clinical trial of a modified Cox maze procedure with bipolar radiofrequency ablation | Q38516282 | ||
| Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes | Q38607671 | ||
| Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation | Q38635098 | ||
| The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis | Q39523454 | ||
| Use of ramipril in preventing stroke: double blind randomised trial | Q39524006 | ||
| Amiodarone in pregnancy. Case report and review of the literature | Q39526884 | ||
| Occult thyrotoxicosis: A correctable cause of “idiopathic” atrial fibrillation | Q39668631 | ||
| Accepted, controversial, and speculative aspects of ventricular defibrillation | Q40293622 | ||
| Obesity and risk of new-onset atrial fibrillation after cardiac surgery | Q40372903 | ||
| Risk of sudden arrhythmic death in the Wolff-Parkinson-White syndrome: current perspectives | Q40390429 | ||
| Left atrial appendage "stunning" after spontaneous conversion of atrial fibrillation demonstrated by transesophageal Doppler echocardiography. | Q40444205 | ||
| Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardioversion from atrial fibrillation and flutter: an analysis of pooled trials | Q40567231 | ||
| Immediate reinitiation of atrial fibrillation after electrical cardioversion predicts subsequent pharmacologic and electrical conversion to sinus rhythm and amiodarone | Q40735045 | ||
| The optimal technique for electrical cardioversion of atrial fibrillation | Q40742994 | ||
| Myocardial sarcoidosis | Q40867912 | ||
| Natural history of left atrial spontaneous echo contrast in nonrheumatic atrial fibrillation | Q40879354 | ||
| Identification of a genetic locus for familial atrial fibrillation | Q40900354 | ||
| β-Blockers are effective in congestive heart failure patients with atrial fibrillation | Q44635746 | ||
| Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways | Q44653104 | ||
| Reproducible efficacy of loading oral propafenone in restoring sinus rhythm in patients with paroxysmal atrial fibrillation | Q44668366 | ||
| Disopyramide in the prevention of recurrence of atrial fibrillation after electroconversion | Q69352715 | ||
| Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter | Q69368479 | ||
| Usefulness of atrial fibrillation as a predictor of stroke after isolated coronary artery bypass grafting | Q69413883 | ||
| Reversibility of tachycardia-induced left ventricular dysfunction after closed-chest catheter ablation of the atrioventricular junction for intractable atrial fibrillation | Q69461347 | ||
| Usefulness of propafenone for recurrent paroxysmal atrial fibrillation | Q69491616 | ||
| Improved control of atrial fibrillation with combined pindolol and digoxin therapy | Q69580054 | ||
| Cerebral blood flow before and after cardioversion of atrial fibrillation | Q69600228 | ||
| Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy | Q69742234 | ||
| Risk of stroke in non-rheumatic atrial fibrillation | Q69894816 | ||
| Effect of pregnancy on pressure gradient in mitral stenosis | Q69940857 | ||
| ??? | Q64816475 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | atrial fibrillation | Q815819 |
| P304 | page(s) | e257-e354 | |
| P577 | publication date | 2006-08-15 | |
| P1433 | published in | Circulation | Q578091 |
| P478 | volume | 114 |
| Q22306346 | 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration |
| Q30653045 | 2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures |
| Q35536198 | 3D virtual human atria: A computational platform for studying clinical atrial fibrillation |
| Q34398295 | A Non-Surgeon's Guide to Surgical Management of Atrial Fibrillation |
| Q54912154 | A Study on the Occurrence and Prevention of Perioperative Stroke after Coronary Artery Bypass Grafting. |
| Q37523156 | A brief overview of surgery for atrial fibrillation |
| Q42180709 | A canine model of sustained atrial fibrillation induced by rapid atrial pacing and phenylephrine. |
| Q35986742 | A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: balancing the risks and benefits |
| Q36203602 | A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation |
| Q34540512 | A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk in Communities [ARIC] study). |
| Q44571178 | A comparative study between amiodarone and magnesium sulfate as antiarrhythmic agents for prophylaxis against atrial fibrillation following lobectomy |
| Q46990972 | A computer-aided diagnostic algorithm improves the accuracy of transesophageal echocardiography for left atrial thrombi: a single-center prospective study |
| Q38419890 | A dedicated cardioversion unit for the treatment of atrial fibrillation. Reducing costs by optimizing processes |
| Q52990577 | A low-dose, dual-phase cardiovascular CT protocol to assess left atrial appendage anatomy and exclude thrombus prior to left atrial intervention. |
| Q34278784 | A meta-analysis of omega-3 fatty acids and incidence of atrial fibrillation |
| Q36644851 | A multidisciplinary atrial fibrillation clinic |
| Q36974348 | A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score |
| Q81154485 | A non-invasive method to predict electrical cardioversion outcome of persistent atrial fibrillation |
| Q43067898 | A perspective on DIONYSOS. |
| Q50924621 | A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers. |
| Q36982811 | A practical approach to the management of patients with atrial fibrillation |
| Q33161569 | A primer on arrhythmias in patients with hypertrophic cardiomyopathy |
| Q27026830 | A systematic review of validated methods for identifying atrial fibrillation using administrative data |
| Q33773745 | A variant of IL6R is associated with the recurrence of atrial fibrillation after catheter ablation in a Chinese Han population |
| Q33378876 | AFFECT: a prospective, open-label, multicenter trial to evaluate the feasibility and safety of a short-term treatment with subcutaneous certoparin in patients with persistent non-valvular atrial fibrillation |
| Q37495744 | Ablation of Atrial Fibrillation in the Elderly: Current Evidence and Evolving Trends |
| Q86497135 | Ablation of atrial fibrillation |
| Q36867280 | Ablation should not be first-line therapy for the treatment of atrial fibrillation |
| Q46222785 | Absence of calcium channel alpha1C-subunit mutation in human atrial fibrillation |
| Q37208100 | Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles. |
| Q42754309 | Acute disabling low-back pain during intravenous administration of amiodarone: could intravenous to oral switch therapy be a safe strategy? |
| Q90324858 | Acute embolic stroke in a patient with atrial fibrillation after electroconvulsive therapy |
| Q28681506 | Acute exposure to air pollution triggers atrial fibrillation |
| Q53164845 | Acute knee haemarthrosis: a case report describing diagnosis and management for a patient on anticoagulation medication. |
| Q36460629 | Adherence to Guidelines for Antithrombotic Therapy in Patients with Atrial Fibrillation According to CHADS2 Score before and after Stroke: A Multicenter Observational Study from Korea |
| Q85855408 | Adjunctive surgical atrial fibrillation ablation during cardiac surgery: real life experiences |
| Q37157572 | Advances in mechanisms of atrial fibrillation: structural remodeling, high-frequency fractionated electrograms, and reentrant AF drivers |
| Q51132669 | Adverse prognosis of incidentally detected ambulatory atrial fibrillation. A cohort study. |
| Q38500772 | Aetiological diagnosis of middle-aged and elderly cryptogenic ischaemic cerebral vascular disease |
| Q33292258 | Age-related changes in P wave morphology in healthy subjects. |
| Q37923976 | Aging is a primary risk factor for cardiac arrhythmias: disruption of intracellular Ca2+ regulation as a key suspect |
| Q36098769 | Alcohol and vagal tone as triggers for paroxysmal atrial fibrillation |
| Q34725723 | Alcohol consumption as a risk factor for atrial fibrillation: a systematic review and meta-analysis |
| Q30425918 | American Heart Association atrial fibrillation research summit: a conference report from the American Heart Association |
| Q46428590 | Amiodaron for treatment of perioperative cardiac arrythmia: a broad spectrum antiarrythmetic agent? |
| Q46923343 | Amiodarone and atrial fibrillation. |
| Q38080472 | Amiodarone-induced pulmonary toxicity--a fatal case report and literature review |
| Q33811339 | An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality |
| Q53623654 | An unusual case of flecainide-induced QT prolongation leading to cardiac arrest. |
| Q57575260 | Analysis of QRS-T subtraction in unipolar atrial fibrillation electrograms |
| Q35942115 | Anemia as an Independent Predictor of Adverse Cardiac Outcomes in Patients with Atrial Fibrillation |
| Q28073527 | Anemia: An Independent Predictor Of Adverse Outcomes In Older Patients With Atrial Fibrillation |
| Q38822819 | Anti-arrhythmic strategies for atrial fibrillation: The role of computational modeling in discovery, development, and optimization. |
| Q48752824 | Antiarrhythmic drug therapy for maintaining sinus rhythm early after pulmonary vein ablation in patients with symptomatic atrial fibrillation. |
| Q34945224 | Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease |
| Q24197643 | Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation |
| Q24243067 | Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation |
| Q37914925 | Anticoagulant management in the cardiovascular setting |
| Q33714803 | Anticoagulant use for prevention of stroke in a commercial population with atrial fibrillation |
| Q37496051 | Anticoagulation and Clinical Outcomes in Heart Failure Patients With Atrial Fibrillation: Findings From the ADHERE Registry |
| Q46546595 | Anticoagulation and thrombophilia in pregnancy |
| Q27010464 | Anticoagulation for atrial fibrillation in patients on dialysis: are the benefits worth the risks? |
| Q95806336 | Anticoagulation for atrial fibrillation in the elderly: part 1 |
| Q36956325 | Anticoagulation in atrial fibrillation: selected controversies including optimal anticoagulation intensity, treatment of intracerebral hemorrhage |
| Q51730417 | Anticoagulation in women with nonvalvular atrial fibrillation: insights from clinical trials. |
| Q37168763 | Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population |
| Q38101275 | Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents |
| Q38162123 | Antiplatelet therapy in prevention of cardio- and venous thromboembolic events |
| Q37167694 | Antithrombotic Usage Patterns in the Era of New Oral Anticoagulant Options for Atrial Fibrillation |
| Q37394525 | Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial |
| Q37184220 | Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients |
| Q35752573 | Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Q37990454 | Antithrombotic therapy for stroke prevention in atrial fibrillation and mechanical heart valves |
| Q37275649 | Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician |
| Q47856743 | Antithrombotic triple therapy in a patient with multiple thrombi, subacute myocardial infarction and coronary stent implantation |
| Q38081257 | Antithrombotics for stroke prevention in non-valvular atrial fibrillation: an update |
| Q37953152 | Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence |
| Q36296510 | Application of Wavelet Entropy to predict atrial fibrillation progression from the surface ECG |
| Q35496665 | Appreciating the medical literature: five notable articles in general internal medicine from 2009 and 2010 |
| Q55229155 | Approaches to Left Atrial Appendage Closure: Device Design, Performance, and Limitations. |
| Q36879563 | Arterial embolism. |
| Q33829782 | Ascertainment of warfarin and aspirin use by medical record review compared with automated pharmacy data |
| Q37162895 | Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous? |
| Q37853476 | Assessing patients for catheter ablation during hospitalization for acute heart failure |
| Q48475735 | Assessment of association of rs2200733 on chromosome 4q25 with atrial fibrillation and ischemic stroke in a Chinese Han population |
| Q80651824 | Assessment of atrial electromechanical coupling and influential factors in nonrheumatic paroxysmal atrial fibrillation |
| Q53275818 | Assessment of global function of left ventricle with dual-source CT in patients with severe arrhythmia: a comparison with the use of two-dimensional transthoracic echocardiography |
| Q30480590 | Assessment of mitral bioprostheses using cardiovascular magnetic resonance |
| Q37720750 | Assessment of the adherence of cardiologists to guidelines for the treatment of atrial fibrillation |
| Q55496245 | Association Between Blood Lipid Profiles and Atrial Fibrillation: A Case-Control Study. |
| Q58577562 | Association between P-selectin levels and left atrial blood stasis in patients with nonvalvular atrial fibrillation |
| Q34774717 | Association between familial atrial fibrillation and risk of new-onset atrial fibrillation |
| Q46742284 | Association between outpatient visits following hospital discharge and readmissions among Medicare beneficiaries with atrial fibrillation and other chronic conditions |
| Q34993737 | Association between plaque thickness of the thoracic aorta and recurrence of atrial fibrillation after ablation |
| Q37314489 | Association of Single Nucleotide Polymorphisms with Atrial Fibrillation and the Outcome after Catheter Ablation. |
| Q28709414 | Association of body mass index, diabetes, hypertension, and blood pressure levels with risk of permanent atrial fibrillation |
| Q57682821 | Association of rs2200733 at 4q25 with early onset of lone atrial fibrillation in young patients |
| Q36786572 | Association rules to identify complications of cerebral infarction in patients with atrial fibrillation |
| Q38065252 | Atherosclerosis and thromboembolic risk in atrial fibrillation: focus on peripheral vascular disease. |
| Q37762592 | Athletes and arrhythmias |
| Q37496257 | Atrial Fibrillation Complicating Acute Coronary Syndromes |
| Q35901629 | Atrial Fibrillation Management Strategies in Routine Clinical Practice: Insights from the International RealiseAF Survey |
| Q37114460 | Atrial Fibrillation and Heart Failure |
| Q35097150 | Atrial Fibrosis Helps Select the Appropriate Patient and Strategy in Catheter Ablation of Atrial Fibrillation: A DE-MRI Guided Approach |
| Q41896872 | Atrial arrhythmogenicity in aged Scn5a+/DeltaKPQ mice modeling long QT type 3 syndrome and its relationship to Na+ channel expression and cardiac conduction. |
| Q36295206 | Atrial electromechanical cycle length mapping in paced canine hearts in vivo |
| Q84478469 | Atrial fibrillation (acute onset) |
| Q86069453 | Atrial fibrillation (acute onset) |
| Q33446623 | Atrial fibrillation (acute onset). |
| Q94376911 | Atrial fibrillation (chronic) |
| Q82463769 | Atrial fibrillation (chronic) |
| Q33446641 | Atrial fibrillation (chronic). |
| Q37316579 | Atrial fibrillation after cardiac surgery: where are we now? |
| Q42536338 | Atrial fibrillation after coronary artery bypass grafting |
| Q28680807 | Atrial fibrillation and cognitive decline: a longitudinal cohort study |
| Q37155980 | Atrial fibrillation and congestive heart failure |
| Q36830280 | Atrial fibrillation and congestive heart failure: a two-way street |
| Q35125950 | Atrial fibrillation and death after myocardial infarction: a community study |
| Q38144996 | Atrial fibrillation and heart failure: intersecting populations, morbidities, and mortality |
| Q36551541 | Atrial fibrillation and thromboprophylaxis in heart failure: the need for patient-centered approaches to address adherence |
| Q37635243 | Atrial fibrillation anticoagulation care in a large urban family medicine practice |
| Q37358467 | Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications |
| Q37398114 | Atrial fibrillation in cardiac channelopathies. |
| Q33954432 | Atrial fibrillation in congestive heart failure |
| Q38032181 | Atrial fibrillation in heart failure |
| Q36952103 | Atrial fibrillation in obstructive sleep apnea |
| Q53062472 | Atrial fibrillation in the Malmö Diet and Cancer study: a study of occurrence, risk factors and diagnostic validity. |
| Q86856130 | Atrial fibrillation in the elderly |
| Q43240176 | Atrial fibrillation is a possible marker of frailty in hospitalized patients: results of the GIFA Study |
| Q46238961 | Atrial fibrillation organization: quantification of propofol effects |
| Q36542294 | Atrial fibrillation pacing decreases intravascular shear stress in a New Zealand white rabbit model: implications in endothelial function |
| Q39957513 | Atrial fibrillation significantly increases total mortality and stroke risk beyond that conveyed by the CHADS2 risk factors |
| Q26864767 | Atrial fibrillation therapy now and in the future: drugs, biologicals, and ablation |
| Q55038986 | Atrial fibrillation trial to evaluate real-world procedures for their utility in helping to lower stroke events (AFTER-PULSE): Study protocol for a randomized controlled trial. |
| Q26851235 | Atrial fibrillation: a review of recent studies with a focus on those from the duke clinical research institute |
| Q37923979 | Atrial fibrillation: an epidemic in the elderly |
| Q46936673 | Atrial fibrillation: an observational study with outpatients |
| Q35526930 | Atrial fibrillation: current knowledge and future directions in epidemiology and genomics |
| Q34986419 | Atrial fibrillation: current perspective |
| Q83446442 | Atrial fibrillation: the beat is faster than the answers |
| Q33741873 | Atrial flutter versus atrial fibrillation in a general population: differences in comorbidities associated with their respective onset |
| Q91884593 | Atrioventricular block can be used as a risk predictor of clinical atrial fibrillation |
| Q37855664 | Atrioventricular junction ablation and pacemaker implantation for heart failure associated with atrial fibrillation: potential issues and therapies in the setting of acute heart failure syndrome |
| Q36173753 | Balancing efficacy and bleeding risk in the prevention of stroke due to atrial fibrillation with newer oral anticoagulants |
| Q36905791 | Beat shock proteins and atrial fibrillation. |
| Q36860112 | Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). |
| Q37073803 | Bleeding and stroke risk in a real-world prospective primary prevention cohort of patients with atrial fibrillation |
| Q39121292 | Bleeding complication of triple therapy of rivaroxaban, prasugrel, and aspirin: a case report and general discussion |
| Q33841770 | Bleeding complications associated with warfarin treatment in ischemic stroke patients with atrial fibrillation: a population-based cohort study |
| Q34132273 | Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta-analysis |
| Q33951474 | Body mass index and risk of left atrial thrombus in patients with atrial fibrillation |
| Q51222509 | CHA(2)DS(2)-VASc versus CHADS(2) for stroke risk assessment in low-risk patients with atrial fibrillation: a pilot study from a single center of the NCDR-PINNACLE registry. |
| Q45153373 | CHADS(2) and CHA(2)DS (2)-VASc score of patients with atrial fibrillation or flutter and newly detected left atrial thrombus |
| Q42945112 | Can polymorphisms predict response to antiarrhythmic drugs in atrial fibrillation? |
| Q48229880 | Cardiac hyaluronan may be associated with the persistence of atrial fibrillation |
| Q42946844 | Cardiac mast cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts |
| Q34333051 | Cardiac remodeling as a consequence of atrial fibrillation: An anatomical study of perfusion-fixed human heart specimens |
| Q36628071 | Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation |
| Q37472076 | Cardima Surgical Ablation System: a novel tool for cardiac ablation in the treatment of atrial fibrillation |
| Q27027558 | Cardioembolic stroke: epidemiology |
| Q38176144 | Cardioembolic stroke: practical considerations for patient risk management and secondary prevention |
| Q38042109 | Cardioprotection against ischaemia/reperfusion by vitamins C and E plus n-3 fatty acids: molecular mechanisms and potential clinical applications |
| Q53150011 | Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). |
| Q52898841 | Cardiovascular magnetic resonance imaging for accurate sizing of the left atrium: predictability of pulmonary vein isolation success in patients with atrial fibrillation. |
| Q37573899 | Cardioversion for atrial fibrillation: treatment options and advances |
| Q28972392 | Cardioversion: Past, Present, and Future |
| Q27025527 | Care transitions in anticoagulation management for patients with atrial fibrillation: an emphasis on safety |
| Q64890331 | Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design. |
| Q36867275 | Catheter ablation as first-line therapy for patients with symptomatic atrial fibrillation |
| Q56986662 | Catheter ablation for atrial fibrillation |
| Q43737869 | Catheter ablation of atrial fibrillation in patients at low thrombo-embolic risk: efficacy and safety of a simplified periprocedural anticoagulation strategy |
| Q80188933 | Catheter ablation of atrial fibrillation in patients with hyperthyroidism |
| Q86414206 | Catheter ablation of atrial fibrillation in the young: insights from the German Ablation Registry |
| Q36239947 | Central tendency measure and wavelet transform combined in the non-invasive analysis of atrial fibrillation recordings. |
| Q86553722 | Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD |
| Q86553726 | Chapter 5: Referral to specialists and models of care |
| Q44916617 | Characteristic changes of volume and three-dimensional structure of the left atrium in different forms of atrial fibrillation: predictive value after ablative treatment |
| Q46833445 | Characterization of cardiac oxidative stress levels in patients with atrial fibrillation |
| Q37770110 | Cholesterol and cardiac arrhythmias. |
| Q91912458 | Chronic Obstructive Pulmonary Disease: Inpatient Management |
| Q36533520 | Chronic kidney disease: an independent risk factor of all-cause mortality for elderly Chinese patients with chronic heart failure |
| Q33585586 | Classification, Etiology and Clinical Evaluation of Atrial Fibrillation |
| Q39325539 | Clinical and Cost Effectiveness of Apixaban Compared to Aspirin in Patients with Atrial Fibrillation: An Australian Perspective |
| Q89182047 | Clinical characteristics and outcomes in super-elderly patients (>85 years) with heart failure: single center observational study in Japan |
| Q28218274 | Clinical experience with the Bicarbon heart valve prosthesis |
| Q48761940 | Clinical features of patients with left atrial thrombus undergoing anticoagulant therapy. |
| Q34621707 | Clinical implications of recent trials on anticoagulation in patients with atrial fibrillation |
| Q42876187 | Clinical observation on the treatment of atrial fibrillation with amiodarone combined with Shenmai Injection (参麦注射液). |
| Q38095871 | Clinical update on the management of atrial fibrillation. |
| Q37002176 | Clinical use of and future perspectives on antiarrhythmic drugs. |
| Q87611105 | Clinical utility and prognostic significance of measuring troponin I levels in patients presenting to the emergency room with atrial fibrillation |
| Q36968781 | Coagulation assessment with the new generation of oral anticoagulants |
| Q51221468 | Combined saturation/inversion recovery sequences for improved evaluation of scar and diffuse fibrosis in patients with arrhythmia or heart rate variability. |
| Q37115694 | Commentary on : New-Onset Atrial Fibrillation Predicts Long-Term Mortality After Coronary Artery Bypass Graft by El-chami et.al |
| Q36949441 | Common genetic polymorphism at 4q25 locus predicts atrial fibrillation recurrence after successful cardioversion |
| Q33854824 | Common variants in KCNN3 are associated with lone atrial fibrillation |
| Q38162889 | Comparative effectiveness of antiarrhythmic drugs on cardiovascular hospitalization and mortality in atrial fibrillation |
| Q38051103 | Comparative effectiveness of catheter ablation strategies for rhythm control in patients with atrial fibrillation: a meta-analysis |
| Q37307689 | Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation. |
| Q30814514 | Comparative safety of periablation anticoagulation strategies for atrial fibrillation: data from a large multicenter study |
| Q36587229 | Comparison of Atrial Fibrillation in the Young versus That in the Elderly: A Review |
| Q51464117 | Comparison of Microlife BP A200 Plus and Omron M6 blood pressure monitors to detect atrial fibrillation in hypertensive patients. |
| Q47097687 | Comparison of the CHADS2, CHA2DS2-VASc and R2CHADS2 Scores in Japanese Patients with Non-valvular Paroxysmal Atrial Fibrillation Not Receiving Anticoagulation Therapy |
| Q42025251 | Comparison of the effects of bepridil and aprindine for the prevention of atrial fibrillation after cardiac and aortic surgery: A prospective randomized study |
| Q44113148 | Comparison of the impact of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management trial on prescribing patterns: a time-series analysis |
| Q36838571 | Completion of guideline-recommended initial evaluation of atrial fibrillation |
| Q37495658 | Complications of Radiofrequency Catheter Ablation for Atrial Fibrillation |
| Q38377941 | Computational fluid dynamics modelling of left valvular heart diseases during atrial fibrillation. |
| Q31103589 | Computational mapping identifies localized mechanisms for ablation of atrial fibrillation |
| Q38020423 | Computational modeling of the human atrial anatomy and electrophysiology |
| Q38790646 | Computed Tomography Imaging in Atrial Fibrillation Ablation |
| Q34548105 | Computed tomography for detecting left atrial thrombus: a meta-analysis |
| Q49588125 | Continued Use of Antiplatelet Agent May Increase the Risk of Delayed Bleeding After Endoscopic Submucosal Dissection. |
| Q48662968 | Conventional pulmonary vein isolation compared with the "box isolation" method: a randomized clinical trial |
| Q51104318 | Cost comparison of catheter ablation and medical therapy in atrial fibrillation. |
| Q45893042 | Cost of hospital admission for antiarrhythmic drug initiation in atrial fibrillation |
| Q40523358 | Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek healthcare setting |
| Q37194595 | Cost-effectiveness of catheter ablation for rhythm control of atrial fibrillation |
| Q37382857 | Cost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation |
| Q48435047 | Could exercise be a new strategy to revert some patients with atrial fibrillation? |
| Q41785817 | Cryoballoon catheter ablation in atrial fibrillation |
| Q84427497 | Cryoballoon pulmonary vein isolation temporarily modulates the intrinsic cardiac autonomic nervous system |
| Q37044645 | Curing atrial fibrillation: Two decades of progress |
| Q37990564 | Current anticoagulant safety |
| Q46271907 | Current atrial fibrillation guidelines and therapy algorithms: are they adequate? |
| Q34048260 | Current perceptions of the epidemiology of atrial fibrillation |
| Q46150475 | Current strategies in the treatment of atrial fibrillation |
| Q37140198 | Current strategies to minimize the bleeding risk of warfarin |
| Q37444697 | Dabigatran Versus Warfarin for Direct Current Cardioversion in Atrial Fibrillation |
| Q37579455 | Dabigatran etexilate: future directions in anticoagulant treatment. |
| Q84474916 | Dabigatran in atrial fibrillation: pharmacology and clinical trials |
| Q37990337 | Dabigatran: comparison to warfarin, pathway to approval, and practical guidelines for use. |
| Q60620950 | Decision-making around antithrombotics for stroke prevention in atrial fibrillation: the health professionals’ views |
| Q45052852 | Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum |
| Q39036995 | Destruction Of Medium Already Afected By Destructive Disorder: Fibrillating Atria Conceptually Need Therapeutic Help Rather Than Surgical Or Ablative Destruction |
| Q33920454 | Detection of Atrial Fibrillation After Surgical Ablation: Conventional Versus Continuous Monitoring |
| Q37866143 | Detection of atrial fibrillation and secondary stroke prevention using telemetry and ambulatory cardiac monitoring. |
| Q51826226 | Detection of atrial fibrillation using a modified microlife blood pressure monitor. |
| Q36755007 | Detection of paroxysmal atrial fibrillation in stroke/tia patients |
| Q37069336 | Developing a Complex Educational-Behavioural Intervention: The TREAT Intervention for Patients with Atrial Fibrillation |
| Q51357903 | Development of a Computerised Antithrombotic Risk Assessment Tool (CARAT) to optimise therapy in older persons with atrial fibrillation. |
| Q30491056 | Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study |
| Q26800991 | Diagnosing Paroxysmal Atrial Fibrillation: Are Biomarkers the Solution to This Elusive Arrhythmia? |
| Q47705606 | Diagnostic accuracy of a new algorithm to detect atrial fibrillation in a home blood pressure monitor. |
| Q82866594 | Diagnostic performance of 320-detector CT coronary angiography in patients with atrial fibrillation: preliminary results |
| Q48391857 | Diagnostic yield of external loop recording in patients with acute ischemic stroke or TIA. |
| Q33726160 | Dietary fish intake and incident atrial fibrillation (from the Women's Health Initiative). |
| Q35966775 | Differences in anticoagulant therapy prescription in patients with paroxysmal versus persistent atrial fibrillation |
| Q37600507 | Different types of atrial fibrillation, renal function, and mortality in elderly Chinese patients with coronary artery disease |
| Q38565140 | Digoxin: its role in contemporary medicine |
| Q38415536 | Direct oral anticoagulants in the secondary prevention of stroke and transient ischemic attack in patients with atrial fibrillation |
| Q38087189 | Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation |
| Q24197843 | Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation |
| Q36752772 | Do we need pharmacological therapy for atrial fibrillation in the ablation era? |
| Q42134752 | Does Type D Personality Impact on the Prognosis of Patients Who Underwent Catheter Ablation for Atrial Fibrillation? A 1-Year Follow-Up Study |
| Q54475197 | Downregulation of peroxisome proliferator-activated receptor-gamma expression in hypertensive atrial fibrillation. |
| Q37815205 | Dronedarone as a new treatment option for atrial fibrillation patients: pharmacokinetics, pharmacodynamics and clinical practice |
| Q33992727 | Dronedarone in patients with congestive heart failure: insights from ATHENA. |
| Q42836717 | Dronedarone or amiodarone for rhythm control for atrial fibrillation: implications from the DIONYSOS study |
| Q89825678 | Dronedarone treatment following cardioversion in patients with atrial fibrillation/flutter: A post hoc analysis of the EURIDIS and ADONIS trials |
| Q28295175 | Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter |
| Q34239793 | Dronedarone: evidence supporting its therapeutic use in the treatment of atrial fibrillation |
| Q34421568 | Durability of class I American College of Cardiology/American Heart Association clinical practice guideline recommendations |
| Q57118621 | Dynamic Electrocardiography is Useful in the Diagnosis of Persistent Atrial Fibrillation Accompanied with Second-Degree Atrioventricular Block |
| Q36035757 | Dynamic inversion time for improved 3D late gadolinium enhancement imaging in patients with atrial fibrillation |
| Q55041184 | Dynamic stroke risk scores of atrial fibrillation. |
| Q50925485 | Dynamics of AV coupling during human atrial fibrillation: role of atrial rate. |
| Q49197579 | Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study. |
| Q46830286 | Economic burden and disparities in healthcare resource use among adult patients with cardiac arrhythmia |
| Q26764998 | Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism |
| Q24202280 | Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation |
| Q24234691 | Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation |
| Q36335405 | Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. |
| Q92385076 | Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial |
| Q91795638 | Effect of c-Ski on atrial remodelling in a rapid atrial pacing canine model |
| Q87616894 | Effect of catheter ablation on the left ventricular mass index and other echocardiograph parameters in atrial fibrillation patients: comparison with antiarrhythmic drug treatment |
| Q38409730 | Effective practical management of patients with atrial fibrillation when using new oral anticoagulants |
| Q64106406 | Effectiveness and safety of electrical cardioversion for acute-onset atrial fibrillation in the emergency department: a real-world 10-year single center experience |
| Q35499647 | Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation |
| Q45908804 | Effectiveness of a strategy to reduce major vascular complications from catheter ablation of atrial fibrillation. |
| Q30501645 | Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association |
| Q55053962 | Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association. |
| Q36172684 | Effects of Atorvastatin (80 mg) Therapy on Quantity of Epicardial Adipose Tissue in Patients Undergoing Pulmonary Vein Isolation for Atrial Fibrillation |
| Q34791538 | Effects of atrial fibrillation on the outcome of the rehabilitation in patients with cerebral infarction |
| Q44523591 | Effects of dronedarone on clinical outcomes in patients with lone atrial fibrillation: pooled post hoc analysis from the ATHENA/EURIDIS/ADONIS studies |
| Q36321852 | Effects of propranolol on fear of dental extraction: study protocol for a randomized controlled trial |
| Q49177940 | Efficacy and Safety of Warfarin Experience in a Stroke Polyclinic in Stroke Patients. |
| Q34134664 | Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial |
| Q34805855 | Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter |
| Q34505587 | Efficacy of adjunctive ablation of complex fractionated atrial electrograms and pulmonary vein isolation for the treatment of atrial fibrillation: a meta-analysis of randomized controlled trials |
| Q44976035 | Efficacy of landiolol hydrochloride for atrial fibrillation after open heart surgery |
| Q82983062 | Efficacy of low-dose landiolol, an ultrashort-acting β-blocker, on postoperative atrial fibrillation in patients undergoing pulmonary resection for lung cancer |
| Q59200971 | Eicosapentaenoic Acid for the Prevention of Recurrent Atrial Fibrillation |
| Q58865260 | Electroanatomic Properties of the Pulmonary Veins: Slowed Conduction, Low Voltage and Altered Refractoriness in AF Patients |
| Q51916001 | Electrocardiographic characteristics of fibrillatory waves in new-onset atrial fibrillation. |
| Q34919496 | Electromechanical wave imaging for arrhythmias |
| Q35851619 | Electrophysiological function of the retina and optic nerve in patients with atrial fibrillation |
| Q42426708 | Embolic Risk Is Time-dependent |
| Q64288965 | Empowering podiatrists to perform pulse checks for opportunistic atrial fibrillation detection during annual diabetes foot checks |
| Q39300822 | Epicardial Fat and Atrial Fibrillation: A Review |
| Q33786841 | Epidemiology and Management of Atrial Fibrillation and Stroke: Review of Data from Four European Countries. |
| Q33676731 | Epidemiology of the relationship between atrial fibrillation and heart failure |
| Q33714864 | Erratum: utilization of anticoagulation therapy in medicare patients with nonvalvular atrial fibrillation |
| Q41808334 | Esophageal electric fields are predictive of atrial cardioversion success-a finite element analysis |
| Q39094937 | Estimating the prevalence of atrial fibrillation from a three-class mixture model for repeated diagnoses |
| Q40017187 | Evaluation of digoxin concentration after loading dose in patients with renal dysfunction |
| Q33578025 | Evaluation of the Pulmonary Veins and Left Atrial Volume using Multidetector Computed Tomography in Patients Undergoing Catheter Ablation for Atrial Fibrillation |
| Q35020200 | Evaluation of the left atrial substrate in patients with lone atrial fibrillation using delayed-enhanced MRI: implications for disease progression and response to catheter ablation |
| Q33395099 | Evidence and Value: Impact on DEcisionMaking--the EVIDEM framework and potential applications |
| Q42962900 | Evidence-based study on antithrombotic therapy in patients at risk of a stroke with paroxysmal atrial fibrillation |
| Q38170289 | Exercise capacity and paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy |
| Q82079500 | Exercise heart rate acceleration patterns during atrial fibrillation and sinus rhythm |
| Q42433032 | Explaining the RE-LY Trial. |
| Q47663774 | Factors Associated with Anticoagulation Delay Following New-Onset Atrial Fibrillation. |
| Q35201213 | Falling between the cracks: a case of amiodarone toxicity |
| Q36721168 | Falls and Atrial Fibrillation in Elderly Patients |
| Q57260272 | Familial clustering of atrial fibrillation and comparative longitudinal outcomes of familial and non-familial atrial fibrillation |
| Q50247248 | Feasibility of in vivo transesophageal cardiac ablation using a phased ultrasound array. |
| Q45795934 | Finding value in imaging: what is appropriate? |
| Q38957175 | First Diagnosis of Atrial Fibrillation at the Time of Stroke |
| Q92994482 | Flecainide Toxicity Resulting in Pacemaker Latency and Intermittent Failure to Capture |
| Q38386022 | Fluid dynamics of heart valves during atrial fibrillation: a lumped parameter-based approach |
| Q80352909 | Focus on thrombosis : Applying management guidelines in clinical practice |
| Q30487406 | Forward-looking intracardiac ultrasound imaging using a 1-D CMUT array integrated with custom front-end electronics. |
| Q34826211 | Frequency and risk factors for under- and over-treatment in stroke prevention for patients with non-valvular atrial fibrillation in general practice |
| Q58209312 | Frequent Early Cardiac Complications Contribute to Worse Stroke Outcome in Atrial Fibrillation |
| Q35023591 | Frequent periodic leg movement during sleep is an unrecognized risk factor for progression of atrial fibrillation |
| Q48571546 | Gaps in monitoring during oral anticoagulation: insights into care transitions, monitoring barriers, and medication nonadherence |
| Q42936136 | General anaesthesia for external electrical cardioversion of atrial fibrillation: experience of an exclusively cardiological procedural management |
| Q91792296 | Genetic basis of atrial fibrillation |
| Q36876093 | Genetic mechanisms of atrial fibrillation: impact on response to treatment |
| Q37777419 | Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk |
| Q34710843 | Genetics of atrial fibrillation: implications for future research directions and personalized medicine |
| Q55252096 | Giant Left Ventricular Thrombus in a Patient with Acute Ischemic Stroke: A Case Report and Minireview. |
| Q35223184 | Global epidemiology of atrial fibrillation |
| Q44045095 | Global left ventricular longitudinal systolic strain as a major predictor of cardiovascular events in patients with atrial fibrillation. |
| Q44470824 | Glycated hemoglobin and risk of first episode stroke in diabetic patients with atrial fibrillation: A cohort study |
| Q22306361 | Guidelines for the Prevention of Stroke in Women: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association |
| Q37251490 | Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association |
| Q48875887 | Guidelines' criteria for rate control in atrial fibrillation: are they useful? |
| Q33815633 | HRS policy statement: clinical cardiac electrophysiology fellowship curriculum: update 2011 |
| Q46861633 | Heart failure enhances arrhythmogenesis in pulmonary veins |
| Q37744960 | Heart failure in the elderly: advances and challenges |
| Q92357849 | Heparin bridge is associated with more post-polypectomy bleeding and emergency department visits among anticoagulated patients |
| Q37496319 | High Incidence of Atrial Fibrillation or Flutter in Stroke Patients Who Have the Clinical Risk Factors for Stroke |
| Q48344703 | High prevalence of obstructive sleep apnea in patients with resistant paroxysmal atrial fibrillation after pulmonary vein isolation |
| Q46616348 | High sensitivity of the sheep pulmonary vein antrum to acetylcholine stimulation |
| Q47871562 | Holter Monitorisation Results in Early Period of Acute Ischemic Stroke |
| Q38790375 | Homogenization of Atrial Electrical Activities: Conceptual Restoration of Regional Electrophysiological Parameters to Deter Ischemia-Dependent Conflictogenic Atrial Fibrillation |
| Q35554742 | Hospital costs associated with atrial fibrillation for patients with ischemic stroke aged 18-64 years in the United States. |
| Q99623015 | Ibutilide with magnesium for conversion of atrial fibrillation or flutter in rheumatic heart disease patients: Ibutilide with magnesium for chemical cardioversion of atrial fibrillation or flutter |
| Q53306164 | Imaging of pulmonary vein anatomy using low-dose prospective ECG-triggered dual-source computed tomography. |
| Q53455084 | Impact of atrial fibrillation on the cardiovascular system through a lumped-parameter approach. |
| Q36441477 | Impact of genetic polymorphisms on clinical response to antithrombotics |
| Q34633608 | Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial |
| Q43548456 | Impact of image integration on catheter ablation for atrial fibrillation using three-dimensional electroanatomic mapping: a meta-analysis |
| Q33811334 | Impact of the control of symptomatic paroxysmal atrial fibrillation on health-related quality of life. |
| Q35059670 | Improving ablation strategies for the treatment of atrial fibrillation |
| Q34195562 | Improving guideline adherence in the treatment of atrial fibrillation by implementing an integrated chronic care program |
| Q30318791 | In Process Citation |
| Q43980289 | Incidence and significance of early recurrences associated with different ablation strategies for AF: a STAR-AF substudy |
| Q33899134 | Incidence of atrial fibrillation in patients with either heart failure or acute myocardial infarction and left ventricular dysfunction: a cohort study |
| Q60629650 | Incidence of postoperative atrial fibrillation in patients undergoing on-pump and off-pump coronary artery bypass grafting |
| Q87405941 | Incidence of stroke and acute renal failure in patients of postoperative atrial fibrillation after myocardial revascularization |
| Q44036210 | Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: a prospective multicenter cohort study. |
| Q92691063 | Incidence, clinical, electrophysiological characteristics and outcomes of patients with Wolff-Parkinson-White syndrome and atrial fibrillation |
| Q38847043 | Incidence, risk factors and prognosis of postoperative atrial arrhythmias after lung transplantation: a systematic review and meta-analysis |
| Q40551201 | Incident atrial fibrillation and the risk of fracture in the cardiovascular health study |
| Q37862925 | Incidental atrial fibrillation and its management |
| Q46851994 | Increased serum HMGB1 is related to oxidative stress in patients with atrial fibrillation |
| Q46306071 | Incremental cost burden to US healthcare payers of atrial fibrillation/atrial flutter patients with additional risk factors |
| Q34298664 | Independent susceptibility markers for atrial fibrillation on chromosome 4q25. |
| Q36168690 | Individual and Combined Risk Factors for Incident Atrial Fibrillation and Incident Stroke: An Analysis of 3 Million At-Risk US Patients |
| Q59328845 | Indoxyl Sulphate is Associated with Atrial Fibrillation Recurrence after Catheter Ablation |
| Q89518990 | Inflammatory cell infiltration in left atrial appendageal tissues of patients with atrial fibrillation and sinus rhythm |
| Q40469080 | Influence of Competing Risks on Estimating the Expected Benefit of Warfarin in Individuals with Atrial Fibrillation Not Currently Taking Anticoagulants: The Anticoagulation and Risk Factors in Atrial Fibrillation Study. |
| Q45937530 | Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients. |
| Q42459986 | Inhibition of IK,ACh current may contribute to clinical efficacy of class I and class III antiarrhythmic drugs in patients with atrial fibrillation |
| Q50868896 | Interleukin-37 elevation in patients with atrial fibrillation. |
| Q58092864 | Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review |
| Q45717860 | Intra-procedural imaging of the left atrium and pulmonary veins with rotational angiography: a comparison of anatomy obtained by pre-procedural cardiac computed tomography and trans-thoracic echocardiography |
| Q35793597 | Intracardiac atrial defibrillation |
| Q43205535 | Intraprocedural use of ibutilide to organize and guide ablation of complex fractionated atrial electrograms: preliminary assessment of a modified step-wise approach to ablation of persistent atrial fibrillation |
| Q37833065 | Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation |
| Q37115689 | Is AF Ablation Cost Effective? |
| Q37799252 | Is AF Ablation Cost Effective? |
| Q43858415 | Is appropriate management of atrial fibrillation in primary care a utopia? |
| Q36195494 | Is the Preoperative Administration of Amiodarone or Metoprolol More Effective in Reducing Atrial Fibrillation: After Coronary Bypass Surgery? |
| Q50502242 | Japanese Society for Dialysis Therapy guidelines for management of cardiovascular diseases in patients on chronic hemodialysis. |
| Q90623773 | Knowledge, attitude, and practice regarding atrial fibrillation among neurologists in central China: A cross-sectional study |
| Q34029276 | Lack of association between rs3807989 in cav1 and atrial fibrillation |
| Q35575039 | Large-scale candidate gene analysis in whites and African Americans identifies IL6R polymorphism in relation to atrial fibrillation: the National Heart, Lung, and Blood Institute's Candidate Gene Association Resource (CARe) project |
| Q94322527 | Left atrial appendage closure versus oral anticoagulation for preventing stroke in people with atrial fibrillation |
| Q39570419 | Left atrial appendage occlusion and ligation devices: what is available, how to implement them, and how to manage and avoid complications. |
| Q34254113 | Left atrial appendage thrombus detected by intraoperative transesophageal echocardiography in a patient with acute small bowel infarction -A case report-. |
| Q53351914 | Left atrial appendage: morphology and function in patients with paroxysmal and persistent atrial fibrillation. |
| Q34282120 | Left atrial epicardial adiposity and atrial fibrillation |
| Q51503616 | Left atrial lesion formation and volume overload by open irrigation ablation technology during pulmonary vein antrum isolation: acute effects on cardiac hemodynamics. |
| Q42266021 | Left atrial remodeling: Regional differences between paroxysmal and persistent atrial fibrillation |
| Q30464218 | Left atrial reservoir function predicts atrial fibrillation recurrence after catheter ablation: a two-dimensional speckle strain study |
| Q43418738 | Left atrial reverse remodeling and prevention of progression of atrial fibrillation with atrial resynchronization device therapy utilizing dual-site right atrial pacing in patients with atrial fibrillation refractory to antiarrhythmic drugs or cathe |
| Q33722721 | Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. |
| Q35102156 | Left atrial transcriptional changes associated with atrial fibrillation susceptibility and persistence |
| Q35587911 | Left ventricular hypertrophy and antiarrhythmic drugs in atrial fibrillation: impact on mortality |
| Q39300535 | Lone AF - Etiologic Factors and Genetic Insights into Pathophysiolgy |
| Q36926402 | Lone atrial fibrillation: influence of familial disease on gender predilection |
| Q44427484 | Long-term efficacy and safety of two different rhythm control strategies in elderly patients with symptomatic persistent atrial fibrillation |
| Q46045047 | MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent: initial results in patients. |
| Q42715745 | Magnetic nanoparticles and neurotoxins for treating atrial fibrillation: a new way to get burned? |
| Q45193985 | Magnetically guided irrigated gold-tip catheter ablation of persistent atrial fibrillation--techniques, procedural parameters and outcome. |
| Q38693540 | Management of Newly Diagnosed Atrial Fibrillation in an Outpatient Clinic Setting - Patient's perspectives and experiences |
| Q22242896 | Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology: |
| Q28217428 | Management of atrial fibrillation |
| Q37895394 | Management of atrial fibrillation around the world: a comparison of current ACCF/AHA/HRS, CCS, and ESC guidelines |
| Q37417705 | Management of atrial fibrillation in patients with heart failure: from drug therapy to ablation. |
| Q37448133 | Management of patients with risk factors |
| Q37683793 | Management of postoperative atrial fibrillation and subsequent outcomes in contemporary patients undergoing cardiac surgery: insights from the Society of Thoracic Surgeons CAPS-Care Atrial Fibrillation Registry |
| Q37115340 | Management of the Asymptomatic Patient After Catheter Ablation of Atrial Fibrillation |
| Q37186390 | Maternal cardiac arrhythmias during pregnancy and lactation. |
| Q39323610 | May toxicity of amiodarone be prevented by antioxidants? A cell-culture study. |
| Q39210786 | Maze surgery normalizes left ventricular function in patients with persistent lone atrial fibrillation |
| Q42737176 | Measurement of Left Atrial Pressure is a Good Predictor of Freedom From Atrial Fibrillation. |
| Q33795571 | Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review |
| Q37425137 | Measuring quality of oral anticoagulation care: extending quality measurement to a new field. |
| Q36723709 | Mechanisms of arrhythmias and conduction disorders in older adults |
| Q35209970 | Medication management of atrial fibrillation: emerging therapies for rhythm control and stroke prevention. |
| Q36004061 | Meta-analysis identifies six new susceptibility loci for atrial fibrillation |
| Q41890999 | Meta-analysis of the therapeutic effects of various methods for the treatment of chronic atrial fibrillation |
| Q35690954 | Metabolic stress, reactive oxygen species, and arrhythmia. |
| Q38070298 | MicroRNA regulation of cardiac conduction and arrhythmias |
| Q45152501 | Mid-term outcomes of the modified Cox-maze procedure for elderly patients: a risk analysis for failure |
| Q52589130 | Mineralocorticoid Receptor Antagonism in Patients With Atrial Fibrillation: Findings From the ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Registry. |
| Q84889730 | Minimally invasive cardiac surgery for atrial fibrillation complicated by coronary artery disease: combination of video-assisted pulmonary vein isolation and minimally invasive direct coronary artery bypass |
| Q42281595 | Minimally invasive surgery for atrial fibrillation |
| Q33963917 | Minimally invasive surgical versus catheter ablation for the long-lasting persistent atrial fibrillation |
| Q35845150 | Minimally invasive thoracoscopic hybrid treatment of lone atrial fibrillation: early results of monopolar versus bipolar radiofrequency source |
| Q38303442 | Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation |
| Q34788250 | Modern treatment of atrial fibrillation |
| Q39639701 | Modulation of drug block of the cardiac potassium channel KCNA5 by the drug transporters OCTN1 and MDR1. |
| Q35743953 | Molecular Basis of Gene-Gene Interaction: Cyclic Cross-Regulation of Gene Expression and Post-GWAS Gene-Gene Interaction Involved in Atrial Fibrillation |
| Q43427939 | Molecular basis for class Ib anti-arrhythmic inhibition of cardiac sodium channels |
| Q39850461 | Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. |
| Q50221459 | Multi-morbidity, frailty and self-care: important considerations in treatment with anticoagulation drugs. Outcomes of the AFASTER study. |
| Q36718669 | Multiple downstream proarrhythmic targets for calmodulin kinase II: moving beyond an ion channel-centric focus |
| Q35760791 | Multiscale Entropy of the Heart Rate Variability for the Prediction of an Ischemic Stroke in Patients with Permanent Atrial Fibrillation |
| Q49203906 | Murine Models of Heart Failure with Preserved Ejection Fraction: a "Fishing Expedition". |
| Q37384670 | Myocardial Biopsy In "Idiopathic» Atrial Fibrillation And Other Arrhythmias: Nosological Diagnosis, Clinical And Morphological Parallels, And Treatment. |
| Q34544829 | Myocardial perfusion scintigraphy before and after cardioversion for atrial fibrillation: recovery of quantitative parameters |
| Q47688547 | N-terminal pro-brain natriuretic peptide shows diagnostic accuracy for detecting atrial fibrillation in cryptogenic stroke patients |
| Q35547234 | Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. |
| Q28212823 | National underuse of anti-thrombotic therapy in chronic atrial fibrillation identified from digoxin prescribing |
| Q30421724 | Navigated DENSE strain imaging for post-radiofrequency ablation lesion assessment in the swine left atria |
| Q43827708 | Nearly uniform failure of atrial flutter ablation and continuation of antiarrhythmic agents (hybrid therapy) for the long-term control of atrial fibrillation |
| Q86828223 | Nebivolol in preventing atrial fibrillation following coronary surgery in patients over 60 years of age |
| Q37719641 | New approaches to atrial fibrillation management: treat the patient, not the ECG. |
| Q37184197 | New drugs for atrial fibrillation |
| Q38061141 | New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran |
| Q38068593 | New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation |
| Q35739671 | New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders |
| Q55153283 | New-onset lone atrial fibrillation in pregnancy. |
| Q51320681 | Nodal recovery, dual pathway physiology, and concealed conduction determine complex AV dynamics in human atrial tachyarrhythmias. |
| Q84514501 | Non-invasive atrial fibrillation organization follow-up under successive attempts of electrical cardioversion |
| Q38175211 | Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions |
| Q30497538 | Noninvasive characterization of epicardial activation in humans with diverse atrial fibrillation patterns |
| Q48667741 | Nonpharmacological Correction of Hypersympatheticotonia in Patients with Chronic Coronary Insufficiency and Severe Left Ventricular Dysfunction. |
| Q38155933 | Novel anticoagulants for stroke prevention in atrial fibrillation: safety issues in the elderly |
| Q37481193 | Novel approaches for pharmacological management of atrial fibrillation. |
| Q44343773 | Novel connexin40 missense mutations in patients with familial atrial fibrillation |
| Q37961824 | Novel oral anticoagulants and their role in clinical practice |
| Q43872986 | Novel use of the ultra-short-acting intravenous β1-selective blocker landiolol for supraventricular tachyarrhythmias in patients with congestive heart failure. |
| Q35991797 | Nut consumption and risk of atrial fibrillation in the Physicians' Health Study |
| Q36779767 | Obstructive sleep apnea and atrial fibrillation. |
| Q38204508 | Obstructive sleep apnea and atrial fibrillation: understanding the connection |
| Q40033352 | Optimal Anticoagulation Strategy for Cardioversion in Atrial Fibrillation. |
| Q26744553 | Optimal Duration of Monitoring for Atrial Fibrillation in Cryptogenic Stroke: A Nonsystematic Review |
| Q28200609 | Optimising stroke prevention in non-valvular atrial fibrillation |
| Q38068455 | Oral anticoagulation in elderly adults with atrial fibrillation: integrating new options with old concepts |
| Q36567348 | Oral anticoagulation to reduce risk of stroke in patients with atrial fibrillation: current and future therapies |
| Q37978093 | Oral factor Xa and direct thrombin inhibitors: a clinical perspective |
| Q35681742 | Outcomes After Cardioversion in Atrial Fibrillation Patients Treated with Non-Vitamin K Antagonist Oral Anticoagulants (NOACs): Insights from a Meta-Analysis |
| Q36096144 | Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation |
| Q54425131 | Overview of the non-vitamin K oral anticoagulants for atrial fibrillation. |
| Q38025390 | Oxidative Stress and Microcirculatory Flow Abnormalities in the Ventricles during Atrial Fibrillation. |
| Q35695492 | PD-1/PD-L1 expression on CD(4+) T cells and myeloid DCs correlates with the immune pathogenesis of atrial fibrillation |
| Q37674638 | PM101: intravenous amiodarone formulation changes can improve medication safety |
| Q38599099 | PURLS: A-fib and rate control: don't go too low. |
| Q39300460 | Paroxysmal Lone Atrial Fibrillation Is Associated With An Abnormal Atrial Substrate: Characterizing The "Second Factor". |
| Q51697444 | Paroxysmal atrial fibrillation is uncommon in outpatients with chronic heart failure. |
| Q40902545 | Paroxysmal atrial fibrillation triggered by a monomorphic ventricular couplet in a patient with acute coronary syndrome. |
| Q42680461 | Past alcohol consumption and incident atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study |
| Q42101933 | Pathogenesis of AF: impact on intracardiac signals |
| Q37338932 | Pathophysiology of concomitant atrial fibrillation and heart failure: implications for management |
| Q36085708 | Patient outcomes according to adherence to treatment guidelines for rhythm control of atrial fibrillation |
| Q33637662 | Patients with atrial fibrillation and outcomes of cerebral infarction in those with treatment of warfarin versus no warfarin with references to CHA2DS2-VASc score, age and sex - A Swedish nationwide observational study with 48 433 patients |
| Q42657981 | Patterns and predictors of use of warfarin and other common long-term medications in patients with atrial fibrillation |
| Q36344804 | Patterns of warfarin use and subsequent outcomes in atrial fibrillation in primary care practices. |
| Q88195597 | Percutaneous Coronary Intervention in Patients Who Have an Indication for Oral Anticoagulation - an Evidence-based Approach to Antithrombotic Therapy |
| Q33585665 | Percutaneous Left Atrial Appendage Exclusion Therapy: Who, Why and How? |
| Q26797439 | Percutaneous Left Atrial Appendage Ligation for Stroke Prevention in Atrial Fibrillation |
| Q36867285 | Percutaneous catheter ablation of atrial fibrillation |
| Q35062723 | Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial |
| Q92481065 | Peripheral blood metabolite profiles associated with new onset atrial fibrillation |
| Q36302342 | Persistent atrial fibrillation is associated with worse prognosis than paroxysmal atrial fibrillation in acute cerebral infarction |
| Q50148857 | Persistent iatrogenic atrial septal defect after a single-puncture, double-transseptal approach for pulmonary vein isolation using a remote robotic navigation system: results from a prospective study. |
| Q81228687 | Persistent iatrogenic atrial septal defect after pulmonary vein isolation : incidence and clinical implications |
| Q50505326 | Pharmacokinetics and Bioequivalence of Branded and Generic Formulations of Dofetilide 0.5-mg Capsules After Single-Dose Administration in Healthy Subjects. |
| Q37672717 | Pharmacotherapy for atrial fibrillation in elderly hospitalized patients with comorbid congestive heart failure in australia: A retrospective study |
| Q37465183 | Pharmacotherapy for the secondary prevention of stroke |
| Q37086960 | Physical activity ameliorates cardiovascular health in elderly subjects: the functional role of the β adrenergic system. |
| Q41712275 | Physical activity is associated with a reduced risk of atrial fibrillation in middle-aged and elderly women |
| Q34551073 | Physician's fear of anticoagulant therapy in nonvalvular atrial fibrillation |
| Q37703195 | Pilsicainide |
| Q83397035 | Pinch-off syndrome: a simple test is the best |
| Q51135389 | Plasma oxidative stress and inflammatory biomarkers are associated with the sizes of the left atrium and pulmonary vein in atrial fibrillation patients. |
| Q60138050 | Point-by-point pulmonary vein antrum isolation guided by intracardiac echocardiography and 3D mapping and duty-cycled multipolar AF ablation: effect of multipolar ablation on procedure duration and fluoroscopy time |
| Q36801083 | Poor adherence to anticoagulation guidelines in patients with non-valvular atrial fibrillation treated in a tertiary cardiology unit |
| Q38790527 | Post-operative Atrial Fibrillation - Pathophysiology, Treatment and Prevention |
| Q44046805 | Postdischarge international normalized ratio testing and long-term clinical outcomes of patients with heart failure receiving warfarin: findings from the ADHERE registry linked to Medicare claims |
| Q26852436 | Postoperative arrhythmias after cardiac surgery: incidence, risk factors, and therapeutic management |
| Q58602188 | Postoperative atrial fibrillation after cesarean delivery |
| Q36988026 | Postoperative metabolic acidosis following the minimally invasive radiofrequency maze procedure |
| Q90349962 | Posttraumatic Stress Disorder and Risk for Early Incident Atrial Fibrillation: A Prospective Cohort Study of 1.1 Million Young Adults |
| Q41146607 | Potential Biological Markers of Atrial Fibrillation: A Chance to Prevent Cryptogenic Stroke |
| Q37382897 | Practical Issues to Prevent Stroke Associated with Non-valvular Atrial Fibrillation |
| Q38151988 | Practical considerations in the use of novel oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation |
| Q58099349 | Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review |
| Q37254773 | Predicting ischaemic stroke subtype from presenting systolic blood pressure: the BASIC Project. |
| Q51104720 | Predicting termination of paroxysmal atrial fibrillation using empirical mode decomposition of the atrial activity and statistical features of the heart rate variability. |
| Q37366545 | Prediction of HIV acquisition among men who have sex with men. |
| Q96303825 | Predictive value of noninducibility after catheter ablation for paroxysmal and persistent atrial fibrillation |
| Q36552409 | Predictive value of pre-procedural autoantibodies against M2-muscarinic acetylcholine receptor for recurrence of atrial fibrillation one year after radiofrequency catheter ablation |
| Q38202066 | Predictors of long-term maintenance of normal sinus rhythm after successful electrical cardioversion |
| Q57817732 | Predictors of new oral anticoagulant drug initiation as opposed to warfarin in elderly adults: a retrospective observational study in Southern Italy |
| Q43450811 | Predictors of newly diagnosed atrial fibrillation in cryptogenic stroke: a cohort study |
| Q42223440 | Predictors of occult paroxysmal atrial fibrillation in cryptogenic strokes detected by long-term noninvasive cardiac monitoring |
| Q37239408 | Predictors of regional variations in hospitalizations following emergency department visits for atrial fibrillation |
| Q47296279 | Predictors of the need for pacemaker implantation after the Cox maze IV procedure for atrial fibrillation |
| Q34150474 | Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis |
| Q35021968 | Predisposing factors associated with development of persistent compared with paroxysmal atrial fibrillation. |
| Q33574003 | Presence Of Left Atrial Appendage Thrombus In Patients Presenting For Left Atrial Ablation Of Atrial Fibrillation Despite Pre-Operative Anticoagulation |
| Q38413756 | Prevalence of atrial fibrillation and the HATCH score: Intensified monitoring of patients with high HATCH score |
| Q35846455 | Prevalence of atrial fibrillation and warfarin use in older patients receiving hemodialysis |
| Q90285943 | Prevalence of atrial fibrillation in acute ischemic stroke patients: A hospital-based study from India |
| Q34805634 | Prevalence of atrial fibrillation in patients with high CHADS2- and CHA2DS2VASc-scores: anticoagulate or monitor high-risk patients? |
| Q64079024 | Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System |
| Q26866343 | Prevention of cardioembolic stroke |
| Q37978190 | Prevention of heart failure in the elderly: when, where and how to begin? |
| Q38076469 | Prevention of post-coronary artery bypass grafting (CABG) atrial fibrillation: efficacy of prophylactic beta-blockers in the modern era: a meta-analysis of latest randomized controlled trials. |
| Q34072190 | Prevention strategies for cardioembolic stroke: present and future perspectives |
| Q37613887 | Primary Prevention of Atherosclerotic Cardiovascular Disease in Women |
| Q37495922 | Primary Prevention of Atrial Fibrillation - The Path Untread |
| Q34987234 | Probable interaction between warfarin and marijuana smoking |
| Q36635551 | Prognostic abilities of different calculation formulas for the glomerular filtration rate in elderly Chinese patients with coronary artery disease |
| Q26781133 | Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis |
| Q35722462 | Prospectively ECG-Triggered Sequential Dual-Source Coronary CT Angiography in Patients with Atrial Fibrillation: Influence of Heart Rate on Image Quality and Evaluation of Diagnostic Accuracy |
| Q53110466 | Prospectively ECG-triggered sequential dual-source coronary CT angiography in patients with atrial fibrillation: comparison with retrospectively ECG-gated helical CT. |
| Q37310379 | Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry |
| Q39250527 | Psychopathology and symptoms of atrial fibrillation: implications for therapy. |
| Q36644426 | Pulmonary vein morphology by free-breathing whole heart magnetic resonance imaging at 3 Tesla versus breathhold multi-detector computed tomography. |
| Q38490444 | QT response after a test dose and during maintenance therapy with AZD1305 in patients with atrial fibrillation: a double-blind, randomized, placebo-controlled trial |
| Q88575831 | QTc interval predicts outcome of catheter ablation in paroxysmal atrial fibrillation patients with type 2 diabetes mellitus |
| Q99550833 | Quality Improvement in Atrial Fibrillation detection after ischaemic stroke (QUIT-AF) |
| Q33891646 | Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression |
| Q45989156 | Quinidine for pharmacological cardioversion of atrial fibrillation: a retrospective analysis in 501 consecutive patients. |
| Q36395199 | Race-specific impact of atrial fibrillation risk factors in blacks and whites in the southern community cohort study |
| Q36147009 | Radiofrequency Catheter Ablation Improves the Quality of Life Measured with a Short Form-36 Questionnaire in Atrial Fibrillation Patients: A Systematic Review and Meta-Analysis |
| Q36829324 | Radiofrequency ablation for treatment of atrial fibrillation |
| Q44997106 | Radiofrequency catheter ablation of atrial fibrillation in older patients: outcomes and complications |
| Q30277039 | Rate Control versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery |
| Q38936964 | Rate control in atrial fibrillation |
| Q36905204 | Rate control in atrial fibrillation, insight into the RACE II study |
| Q35611862 | Rate versus rhythm in atrial fibrillation: and how slow do you go? |
| Q37587470 | Rational patient selection for catheter ablation of atrial fibrillation. |
| Q37523123 | Rationale and design of the Left Atrial Appendage Occlusion Study (LAAOS) III. |
| Q40378922 | Rationale and design of the ODIn-AF Trial: randomized evaluation of the prevention of silent cerebral thromboembolism by oral anticoagulation with dabigatran after pulmonary vein isolation for atrial fibrillation |
| Q47210396 | Real-Life Peak and Trough Dabigatran Plasma Measurements over Time in Hospitalized Geriatric Patients with Atrial Fibrillation |
| Q37990615 | Real-life global survey evaluating patients with atrial fibrillation (REALISE-AF): results of an international observational registry |
| Q44960297 | Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation |
| Q45307497 | Reduced risk of death with warfarin - results of an observational nationwide study of 20 442 patients with atrial fibrillation and ischaemic stroke |
| Q89447282 | Reference effect measures for quantifying, comparing and visualizing variation from random and fixed effects in non-normal multilevel models, with applications to site variation in medical procedure use and outcomes |
| Q93609219 | References |
| Q84140496 | Refining the role of antiplatelet therapy for atrial fibrillation |
| Q84630617 | Relation of gender and interatrial dyssynchrony on tissue Doppler imaging to the prediction of the progression to chronic atrial fibrillation in patients with nonvalvular paroxysmal atrial fibrillation |
| Q37495831 | Relationship Between Arrhythmia and Sleep Disordered Breathing |
| Q92211794 | Relationship between drug application and mortality rate in Chinese older coronary artery disease/chronic heart failure patients with and without low glomerular filtration rate |
| Q53161275 | Relationship between left atrial appendage emptying and left atrial function using cardiac magnetic resonance in patients with atrial fibrillation: comparison with transesophageal echocardiography. |
| Q35130025 | Relationship between obstructive coronary artery disease and abnormal stress testing in patients with paroxysmal or persistent atrial fibrillation. |
| Q37173939 | Relaxin suppresses atrial fibrillation by reversing fibrosis and myocyte hypertrophy and increasing conduction velocity and sodium current in spontaneously hypertensive rat hearts. |
| Q41463324 | Relaxin-2 in Cardiometabolic Diseases: Mechanisms of Action and Future Perspectives |
| Q35473877 | Remote magnetic versus manual catheter navigation for circumferential pulmonary vein ablation in patients with atrial fibrillation |
| Q46357568 | Renal insufficiency should be included in stroke risk scores |
| Q36496360 | Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database |
| Q34759446 | Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. |
| Q53223371 | Respiratory compensation improves the accuracy of electroanatomic mapping of the left atrium and pulmonary veins during atrial fibrillation ablation. |
| Q48179821 | Retrospective Evaluation of the Effect of Heart Rate on Survival in Dogs with Atrial Fibrillation |
| Q64259258 | Reversal effect of Zhigancao decoction on myocardial fibrosis in a rapid pacing-induced atrial fibrillation model in New Zealand rabbits |
| Q48210299 | Reverse atrial electrical remodelling induced by continuous positive airway pressure in patients with severe obstructive sleep apnoea |
| Q37845022 | Review of contemporary antiarrhythmic drug therapy for maintenance of sinus rhythm in atrial fibrillation |
| Q37910798 | Review of the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial: warfarin versus dabigatran |
| Q37831855 | Rhythm control for management of patients with atrial fibrillation: balancing the use of antiarrhythmic drugs and catheter ablation. |
| Q37812344 | Rhythm control strategies and the role of antiarrhythmic drugs in the management of atrial fibrillation: focus on clinical outcomes |
| Q84036536 | Right ventricular rapid pacing in catheter ablation of atrial fibrillation: a novel application for cryoballoon pulmonary vein isolation |
| Q38790565 | Risk Factors for Post-Coronary Artery Bypass Grafting (CABG) Atrial Fibrillation and the Role of Aspirin and Beta Blockers in its Prevention |
| Q33876319 | Risk analysis of new oral anticoagulants for gastrointestinal bleeding and intracranial hemorrhage in atrial fibrillation patients: a systematic review and network meta-analysis |
| Q39300793 | Risk of Arrhythmia Recurrence After Successful Ablation of Lone Atrial Fibrillation |
| Q37118899 | Risk of Malignant Cancer Among Women With New-Onset Atrial Fibrillation |
| Q90584099 | Risk of Recurrent Bleeding Events in Nonvalvular Atrial Fibrillation Treated with Vitamin K Antagonists: A Clinical Practice Research Datalink Study |
| Q33518180 | Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. |
| Q35018887 | Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation |
| Q58715507 | Risk of intracranial hemorrhage (RICH) in users of oral antithrombotic drugs: Nationwide pharmacoepidemiological study |
| Q38888217 | Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants |
| Q34918312 | Risk-benefit ratio assessment for stroke prevention in intermediate risk atrial fibrillation patients: will TEE-based aspirin treatment fill the gap? |
| Q38108855 | Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions. |
| Q64283034 | Robotic navigation shows superior improvement in efficiency for atrial fibrillation ablation |
| Q53170361 | Role for the left atrial appendage occlusion device in managing thromboembolic risk in atrial fibrillation. |
| Q36700759 | Role of Left Ventricular Diastolic Dysfunction in Predicting Atrial Fibrillation Recurrence after Successful Electrical Cardioversion |
| Q58766109 | Role of the CHADS Score in the Evaluation of Carotid Atherosclerosis in Patients with Atrial Fibrillation Undergoing Carotid Artery Ultrasonography |
| Q50327209 | Safety and Efficacy of Inpatient Initiation of Dofetilide versus Sotalol for atrial fibrillation. |
| Q48144701 | Safety and efficacy of oral anticoagulation therapy in Chinese patients with concomitant atrial fibrillation and hypertension |
| Q46001195 | Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation. |
| Q38103541 | Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update |
| Q38091723 | Safety and efficiency of calcium channel blockers versus beta-blockers for rate control in patients with atrial fibrillation and no acute underlying medical illness |
| Q51744693 | Saudi Atrial Fibrillation Survey: national, observational, cross-sectional survey evaluating atrial fibrillation management and the cardiovascular risk profile of patients with atrial fibrillation. |
| Q37599670 | Secondary prophylactic treatment and long-term prognosis after TIA and different subtypes of stroke. A 25-year follow-up hospital-based observational study |
| Q30991603 | Secondhand smoke and atrial fibrillation: Data from the Health eHeart Study |
| Q35988354 | Serial measures of cardiac troponin T levels by a highly sensitive assay and incident atrial fibrillation in a prospective cohort of ambulatory older adults |
| Q38671483 | Sex Differences in the Use of Oral Anticoagulants for Atrial Fibrillation: A Report From the National Cardiovascular Data Registry (NCDR®) PINNACLE Registry |
| Q33572430 | Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study |
| Q37160370 | Should we test for CYP2C9 before initiating anticoagulant therapy in patients with atrial fibrillation? |
| Q43217836 | Significance of cardiac sympathetic nervous system abnormality for predicting vascular events in patients with idiopathic paroxysmal atrial fibrillation |
| Q43057558 | Single nucleotide polymorphisms in inflammatory genes and the risk of early onset of lone atrial fibrillation |
| Q48751644 | Single-ring ablation compared with standard circumferential pulmonary vein isolation using remote magnetic catheter navigation. |
| Q36867371 | Single-step atrial thrombus exclusion and transesophageal cardioversion in atrial fibrillation |
| Q36382368 | Sleep apnea and atrial fibrillation; 2012 update |
| Q48343603 | Sleep disordered breathing and arrhythmia burden in pacemaker recipients |
| Q36586158 | Sleep duration and risk of atrial fibrillation (from the Physicians' Health Study). |
| Q37403214 | Sleep-disordered breathing and atrial fibrillation |
| Q35116195 | Smoking and incidence of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) study |
| Q37496280 | Solutions to Reduce Cardiovascular Events in Patients with Atrial Fibrillation |
| Q54453535 | Spontaneous quadriceps hematoma in an elderly adult taking therapeutic doses of warfarin. |
| Q33984012 | Statin Therapy for Primary Prevention of Atrial Fibrillation: Guided by CHADS2/CHA2DS2VASc Score |
| Q34500520 | Statin therapy for the prevention of atrial fibrillation trial (SToP AF trial) |
| Q36464561 | Status of the epidemiology of atrial fibrillation |
| Q26771564 | Stroke Event Rates and the Optimal Antithrombotic Choice of Patients With Paroxysmal Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| Q30389813 | Stroke Prevention in Atrial Fibrillation and Valvular Heart Disease |
| Q53803663 | Stroke Prevention in Atrial Fibrillation. |
| Q36458873 | Stroke in Atrial Fibrillation - Long-term Follow-up of Cardiovascular Events |
| Q38013062 | Stroke prevention in atrial fibrillation: managing the risks in light of new oral anticoagulants |
| Q37917579 | Stroke prevention in nonvalvular atrial fibrillation |
| Q92378495 | Stroke prevention in patients from Latin American countries with non-valvular atrial fibrillation: Insights from the GARFIELD-AF registry |
| Q37800826 | Stroke prevention in the high-risk atrial fibrillation patient: Medical management |
| Q37810505 | Stroke prevention treatment of patients with atrial fibrillation: old and new. |
| Q36943623 | Stroke risk factors, subtypes, and 30-day case fatality in Abuja, Nigeria |
| Q34030493 | Stroke risk in AF: do AF patterns matter? |
| Q39854204 | Stroke risk stratification in a "real-world" elderly anticoagulated atrial fibrillation population |
| Q38069194 | Stroke risk stratification scores in atrial fibrillation: current recommendations for clinical practice and future perspectives |
| Q36061575 | Study of molecular events in cells by fluorescence correlation spectroscopy. |
| Q33886896 | Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial |
| Q33585597 | Success of Radiofrequency Catheter Ablation of Atrial Fibrillation: Does Obesity Influence the Outcomes? |
| Q49190242 | Superior Vena Cava Syndrome after Radiofrequency Catheter Ablation for Atrial Fibrillation. |
| Q37115702 | Supraventricular Ectopic Activity: When Excessive it is not all Benign! |
| Q42108379 | Surgical ablation for atrial fibrillation: an editorial |
| Q26769985 | Surgical perspectives in the management of atrial fibrillation |
| Q38075000 | Surgical strategies and devices for surgical exclusion of the left atrial appendage: a word of caution |
| Q35071043 | Surgical treatment of atrial fibrillation: a review |
| Q37582479 | Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation |
| Q48375082 | Symptomatic pulmonary embolism among stroke patients in Taiwan: a retrospective cohort study |
| Q28070025 | Symptoms In Atrial Fibrillation: A Contemporary Review And Future Directions |
| Q36108848 | Symptoms and functional status of patients with atrial fibrillation: state of the art and future research opportunities |
| Q35916331 | Tachycardia-bradycardia syndrome in a patient with atrial fibrillation: a case report |
| Q37641421 | Tachycardia-mediated cardiomyopathy: recognition and management |
| Q38099775 | Target specific oral anticoagulants in the management of thromboembolic disease in the elderly |
| Q83835628 | Technical tips for concomitant off-pump epicardial pulmonary vein isolation |
| Q37411934 | The CHA2DS2-VASc score as a predictor of high mortality in hospitalized heart failure patients |
| Q48360646 | The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy |
| Q45146326 | The CHADS2 and CHA 2DS 2-VASc scores predict new occurrence of atrial fibrillation and ischemic stroke |
| Q34008166 | The CHADS2 score predicts ischemic stroke in the absence of atrial fibrillation among subjects with coronary heart disease: data from the Heart and Soul Study |
| Q50856123 | The CHA₂DS₂-VASc score for stroke risk stratification in patients with atrial fibrillation: a brief history. |
| Q30406853 | The Effect of Catheter Ablation on Left Atrial Size and Function for Patients with Atrial Fibrillation: An Updated Meta-Analysis |
| Q36396649 | The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants |
| Q39036918 | The Role of Renal Sympathetic Denervation in Atrial Fibrillation |
| Q36880739 | The ability of NT-proBNP to detect chronic heart failure and predict all-cause mortality is higher in elderly Chinese coronary artery disease patients with chronic kidney disease |
| Q37812378 | The assessment of stroke and bleeding risk in atrial fibrillation: where are we now? |
| Q36639762 | The association between atrial fibrillation and stroke in patients with obstructive sleep apnea: a population-based case-control study |
| Q58597887 | The association of high D-dimer level with high risk of ischemic stroke in nonvalvular atrial fibrillation patients: A retrospective study |
| Q37723861 | The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR. |
| Q37666333 | The business case for quality improvement: oral anticoagulation for atrial fibrillation |
| Q38240097 | The caregiver role in thromboprophylaxis management in atrial fibrillation: a literature review. |
| Q37014482 | The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients |
| Q26823825 | The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms |
| Q40935082 | The cognitive impact of atrial fibrillation |
| Q39254072 | The cost of warfarin treatment for stroke prevention in patients with non-valvular atrial fibrillation in Mexico from a collective perspective |
| Q57653488 | The diagnosis and management of atrial fibrillation in the horse |
| Q33731173 | The economic burden to medicare of stroke events in atrial fibrillation populations with and without thromboprophylaxis |
| Q51247050 | The extracellular isoform of superoxide dismutase has a significant impact on cardiovascular ischaemia and reperfusion injury during cardiopulmonary bypass. |
| Q34178980 | The health care setting rather than medical speciality impacts on physicians adherence to guideline-conform anticoagulation in outpatients with non-valvular atrial fibrillation: a cross sectional survey |
| Q38097972 | The hidden costs of anticoagulation in hospitalized patients with non-valvular atrial fibrillation |
| Q33552630 | The impact of new and emerging clinical data on treatment strategies for atrial fibrillation |
| Q45305835 | The impact of pharmacologic sympathetic and parasympathetic blockade on atrial electrogram characteristics in patients with atrial fibrillation |
| Q48665333 | The impact of type D personality and high-sensitivity C-reactive protein on health-related quality of life in patients with atrial fibrillation. |
| Q45927331 | The importance of atrial fibrillation burden and the origin of device-tailored anticoagulation. |
| Q34534916 | The increasing prevalence of atrial fibrillation among hemodialysis patients |
| Q33384911 | The management of non-valvular atrial fibrillation (NVAF) in Australian general practice: bridging the evidence-practice gap. A national, representative postal survey |
| Q34772923 | The pathology and treatment of cardiac arrhythmias: focus on atrial fibrillation |
| Q37821928 | The pharmaceutical pipeline for atrial fibrillation |
| Q38647868 | The pioneering work of George Mines on cardiac arrhythmias: groundbreaking ideas that remain influential in contemporary cardiac electrophysiology. |
| Q35043849 | The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart failure |
| Q45898311 | The prevalence and risk factors for atrioesophageal fistula after percutaneous radiofrequency catheter ablation for atrial fibrillation: the Canadian experience. |
| Q45344512 | The relationship between electrogram cycle length and dominant frequency in patients with persistent atrial fibrillation. |
| Q98156809 | The risk factors associated with treatment-related mortality in 16,073 kidney transplantation-A nationwide cohort study |
| Q58420963 | The risk of myocardial infarction in patients with atrial fibrillation: an unresolved issue |
| Q48249733 | The stress of sleep in patients prone to atrial tachyarrhythmias |
| Q41858323 | Theoretical considerations for mapping activation in human cardiac fibrillation |
| Q64931128 | Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT-AF. |
| Q61650712 | Therapeutic management in ambulatory elderly patients with atrial fibrillation: The S.AGES cohort |
| Q34668483 | Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: data from the GISSI-AF trial |
| Q37807901 | Thromboembolic risk and anticoagulation strategies in patients undergoing catheter ablation for atrial fibrillation |
| Q51408263 | Thromboembolic risk evaluation in patients with atrial fibrillation using a modified CHADS(2) scoring system. |
| Q39535720 | Towards personalized clinical in-silico modeling of atrial anatomy and electrophysiology. |
| Q89135899 | Transcatheter aortic valve replacement in the setting of left atrial appendage thrombus |
| Q37777185 | Transesophageal Echocardiography for the Diagnosis of Pulmonary Vein Stenosis after Catheter Ablation of Atrial Fibrillation: A Systematic Review |
| Q36957947 | Transitions of care in anticoagulated patients |
| Q41971718 | Transitions of care in anticoagulation management for patients with atrial fibrillation |
| Q92005171 | Transmitral inflow wave and progression from paroxysmal to permanent atrial fibrillation in Asian people |
| Q37109966 | Treating the right patient at the right time: an innovative approach to the management of atrial fibrillation |
| Q37496298 | Treatment Considerations for a Dual Epidemic of Atrial Fibrillation and Heart Failure |
| Q38145265 | Treatment of acute heart failure in the emergency department |
| Q34884620 | Treatment of atrial fibrillation in every days practice |
| Q35648075 | Treatment of risk factors to prevent stroke |
| Q37412464 | Treatment patterns associated with stroke prevention in patients with atrial fibrillation in three major cities in the People's Republic of china |
| Q34056331 | Trends in catheter ablation for atrial fibrillation in the United States |
| Q55381003 | Trends in warfarin use and its associations with thromboembolic and bleeding rates in a population with atrial fibrillation between 1996 and 2011. |
| Q53755450 | Twenty-eight day Holter monitoring is poorly tolerated and insensitive for paroxysmal atrial fibrillation detection in cryptogenic stroke. |
| Q37115706 | Understanding and Managing Atrial Fibrillation in Patients with Kidney Disease |
| Q41568764 | Underuse of oral anticoagulation for individuals with atrial fibrillation in a nursing home setting in France: comparisons of resident characteristics and physician attitude. |
| Q47970384 | Unique histological features of the left atrial posterior wall |
| Q37711335 | Upper Digestive Bleeding in Atrial Fibrillation: Evaluation of Gastroscopy Prior to Oral Anticoagulant Therapy (GOAT), Prospective, Randomized, Double Blind Study on a Community Population |
| Q30000646 | Use of CHADS₂ and CHA₂DS₂-VASc scores to predict subsequent myocardial infarction, stroke, and death in patients with acute coronary syndrome: data from Taiwan acute coronary syndrome full spectrum registry |
| Q37107710 | Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls |
| Q35654365 | Use of oral anticoagulants in African-American and Caucasian patients with atrial fibrillation: is there a treatment disparity? |
| Q34223091 | Use of warfarin in long-term care: a systematic review |
| Q34163339 | Usefulness of a low CHADS2 or CHA2DS2-VASc score to predict normal diagnostic testing in emergency department patients with an acute exacerbation of previously diagnosed atrial fibrillation |
| Q36146288 | Usefulness of brain natriuretic peptide for predicting left atrial appendage thrombus in patients with unanticoagulated nonvalvular persistent atrial fibrillation |
| Q30414713 | Usefulness of pharmacologic conversion of atrial fibrillation during dofetilide loading without the need for electrical cardioversion to predict durable response to therapy |
| Q43067620 | Using explicit criteria to evaluate the quality of prescribing in elderly Italian outpatients: a cohort study |
| Q34765387 | Validation of the Risk Estimator Decision Aid for Atrial Fibrillation (RED-AF) for predicting 30-day adverse events in emergency department patients with atrial fibrillation. |
| Q37823573 | Valvular heart disease: a primer for the clinical pharmacist |
| Q48732017 | Variation in quality of life with type of atrial fibrillation. |
| Q30463868 | Velocity encoded cardiovascular magnetic resonance to assess left atrial appendage emptying |
| Q36764028 | Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent |
| Q37107714 | Vernakalant in the management of atrial fibrillation |
| Q39869983 | Very late recurrences of atrial fibrillation after pulmonary vein isolation |
| Q30595441 | Visualization of epicardial cryoablation lesions using endogenous tissue fluorescence. |
| Q51891359 | Visualization of multiple catheters in left atrial ablation procedures. Comparison of two different 3D mapping systems. |
| Q99241120 | Vitamin K antagonist has a higher impact than heparin in preventing circuit clotting in chronic haemodialysis patients |
| Q38206840 | Vitamin K antagonist use for all patients with hypertrophic cardiomyopathy and atrial fibrillation: analysis of the literature and guideline review |
| Q36872957 | Warfarin for prevention of thrombosis among long-term care residents with atrial fibrillation: evidence of continuing low use despite consideration of stroke and bleeding risk |
| Q37806450 | Warfarin in haemodialysis patients with atrial fibrillation: what benefit? |
| Q46989595 | Warfarin prevails for stroke prevention in atrial fibrillation--even in octogenarians |
| Q37367719 | Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation |
| Q45116644 | Warfarin use in atrial fibrillation patients at low risk for stroke: analysis of the Michigan Anticoagulation Quality Improvement Initiative (MAQI(2)). |
| Q39084555 | What patients want and need to know about atrial fibrillation |
| Q41791076 | Wide Complex Tachycardias: Understanding this Complex Condition Part 2 - Management, Miscellaneous Causes, and Pitfalls. |
| Q34117950 | Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study |
| Q36945029 | Worse stroke outcome in atrial fibrillation is explained by more severe hypoperfusion, infarct growth, and hemorrhagic transformation |
| Q83174369 | [Anticoagulation in atrial fibrillation - an update] |
| Q81746177 | [Atrial fibrillation in the elderly] |
| Q82654611 | [Atrial fibrillation: epidemiologic stakes, definition, and economic aspects] |
| Q79657930 | [Bridging anticoagulation] |
| Q82421243 | [Bridging, interruption and switching of anticoagulants in trauma surgery] |
| Q81646051 | [Complications after ablation of supraventricular tachycardias] |
| Q85334982 | [Dabigatran: transforming the management of oral anticoagulation] |
| Q83315674 | [Epidemiology, clinical picture and management of atrial fibrillation] |
| Q81509770 | [Heart diseases in pregnancy] |
| Q83551949 | [Interventional electrophysiology in cardiac MRI : what is the current status?] |
| Q51276277 | [Knowledge of guidelines for anticoagulation management of patients with atrial fibrillation]. |
| Q84007375 | [New anticoagulant drugs for atrial fibrillation. Feasibility and necessity of monitoring] |
| Q85334978 | [Scope of the latest RE-LY substudies: clinical implications] |
| Q82654639 | [The place of antiarrythmic drugs and rythm control in the treatment of atrial fibrillation] |
| Q85378191 | [Use of cardiac MRI in the field of electrophysiology. Present status and future aspects] |
| Q35971046 | eNOS3 Genetic Polymorphism Is Related to Post-Ablation Early Recurrence of Atrial Fibrillation |
| Q54326621 | β-Blockers on Discharge From Acute Atrial Fibrillation Are Associated With Decreased Mortality and Lower Cerebrovascular Accidents in Patients With Heart Failure and Reduced Ejection Fraction. |
Search more.